≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Nystagmus and other irregular eye movements

DOID EFO Endpoint Browser PheWeb

H7_NYSTAGMUS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — H55
  • Hospital discharge: ICD-9 — 3795
  • Cause of death: ICD-10 — H55
  • Cause of death: ICD-9 — 3795

2 out of 7 registries used, show all original rules.

557

4. Check minimum number of events

None

557

5. Include endpoints

None

557

6. Filter based on genotype QC (FinnGen only)

530

Control definitions (FinnGen only)

Control exclude
H7_EYEOTH

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
H55-H59
Name in latin
Nystagmus et alii motus irregulares oculi

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 4714 2279 2421
Only index persons 3952 1959 1993
Unadjusted period prevalence (%)
Whole population 0.07 0.07 0.07
Only index persons 0.07 0.07 0.08
Median age at first event (years)
Whole population 25.97 30.97 21.18
Only index persons 32.97 36.00 30.00

-FinnGen-

Key figures

All Female Male
Number of individuals 530 318 212
Unadjusted period prevalence (%) 0.11 0.11 0.10
Median age at first event (years) 46.71 44.47 50.07

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
557
Matched controls
5568
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
4503599627370496.0
307.7
545
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.3
70.0
142
289
R42
ICD-10 Finland
Dizziness and giddiness
4.6
64.9
219
683
G35
ICD-10 Finland
Multiple sclerosis
16.6
61.3
53
35
H53.2
ICD-10 Finland
Diplopia
11.1
60.7
68
69
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.4
58.9
140
326
109
Kela drug reimbursment
Multiple sclerosis
16.1
48.1
42
28
AA1AD
NOMESCO Finland
CT of head and brain
3.6
46.2
229
902
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
16.0
41.1
36
24
XCK00
NOMESCO Finland
Perimetry
6.3
41.0
75
135
H50.0
ICD-10 Finland
Convergent concomitant strabismus
14.4
36.8
34
25
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
15.2
36.8
33
23
H81.2
ICD-10 Finland
Vestibular neuronitis
11.0
35.5
39
38
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.2
33.1
99
270
N29
ICPC
Neurological sympt/complt other
11.2
32.5
35
33
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.2
32.4
165
641
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
10.1
31.8
37
39
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.0
30.7
49
76
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
5.1
29.0
65
140
XA800
NOMESCO Finland
Neuropsychological investigation
5.0
28.1
65
144
N03AF02
ATC
oxcarbazepine; oral
6.1
27.4
50
89
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.4
26.8
111
376
G40.9
ICD-10 Finland
Epilepsy, unspecified
6.2
26.8
48
84
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
31.0
26.6
35
12
Z3229
NOMESCO Finland
Other healthcare associate professional
4.1
26.4
81
224
N03AX14
ATC
levetiracetam; systemic
7.2
26.2
40
59
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.1
25.5
78
215
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
7.6
24.9
36
50
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.7
23.7
83
251
3795A
ICD-9 Finland
Other disorders of eye, Nystagmus and other irregular eye movements
+∞
22.0
21
*
H47.2
ICD-10 Finland
Optic atrophy
43.4
20.6
25
6
M03BX01
ATC
baclofen; systemic
7.2
20.6
31
45
L28
ICPC
Limited function/disability (L)
2.8
20.0
123
517
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.8
19.4
111
449
N03AX09
ATC
lamotrigine; oral
4.0
19.0
57
154
N03AE01
ATC
clonazepam; systemic
4.1
18.3
52
135
SPAT1229
SPAT
Assessment of need for aid
4.0
18.1
55
150
TAB00
NOMESCO Finland
Lumbar puncture
4.1
17.8
52
138
Z2446
NOMESCO Finland
Social worker
3.2
17.8
76
260
H52.1
ICD-10 Finland
Myopia
4.2
17.5
48
121
H53.0
ICD-10 Finland
Amblyopia ex anopsia
7.6
17.5
25
34
R27.0
ICD-10 Finland
Ataxia, unspecified
32.6
17.1
22
7
Z2445
NOMESCO Finland
Psychologist
3.7
17.1
58
171
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.8
16.8
54
153
R1250
NOMESCO Finland
Evaluation of functional capability
5.8
15.2
28
50
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.6
15.2
37
85
H52.2
ICD-10 Finland
Astigmatism
5.0
15.1
33
69
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
14.7
168
923
H50.30
ICD-10 Finland
Intermittent esotropy
14.7
14.7
24
17
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
4.9
14.6
33
71
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
153.8
14.5
15
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.0
14.4
67
240
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.5
14.2
101
452
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
6.2
14.0
24
40
N86
ICPC
Multiple sclerosis
18.1
13.9
21
12
H50.1
ICD-10 Finland
Divergent concomitant strabismus
17.2
13.1
20
12
N18
ICPC
Paralysis/weakness
6.3
13.0
22
36
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
6.3
13.0
22
36
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
13.4
13.0
22
17
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
2.8
13.0
68
260
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
6.0
12.8
23
40
TPH04
NOMESCO Finland
Cathetrisation of vein
2.2
12.7
136
722
164
Kela drug reimbursment
Fingolimod
32.9
12.6
16
5
A28
ICPC
Limited function/disability NOS
2.4
12.3
98
460
N03AX18
ATC
lacosamide; systemic
16.3
12.2
19
12
N17
ICPC
Vertigo/dizziness
2.5
12.1
87
389
N28
ICPC
Limited function/disability (N)
9.0
12.1
25
29
L03AB07
ATC
interferon beta-1a; parenteral
13.8
12.0
20
15
N03AX12
ATC
[U] gabapentin; oral
2.3
11.8
101
488
H53.1
ICD-10 Finland
Subjective visual disturbances
3.0
11.8
56
203
H27.0
ICD-10 Finland
Aphakia
30.7
11.7
15
5
H57.1
ICD-10 Finland
Ocular pain
4.0
11.5
33
86
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.1
11.5
50
172
N05BA09
ATC
clobazam; oral
12.2
11.4
20
17
L03AX13
ATC
glatiramer acetate; parenteral
15.4
11.4
18
12
R4130
NOMESCO Finland
Speech therapy
4.0
11.3
32
83
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
11.2
257
1763
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.2
11.1
45
148
N99
ICPC
Neurological disease other
9.5
11.1
22
24
H52.0
ICD-10 Finland
Hypermetropia
4.3
11.0
29
71
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.7
10.9
64
259
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.4
10.9
82
374
N03AG01
ATC
valproic acid; systemic, rectal
3.0
10.8
50
178
Q12.0
ICD-10 Finland
Congenital cataract
28.6
10.8
14
5
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
5.6
10.5
20
37
4AA23, ,
NOMESCO Finland
+∞
10.4
10
*
78112
ICD-8 Finland
Other symptoms referable to nervous system and special senses, Nystagmus
+∞
10.4
10
*
E70.3
ICD-10 Finland
Albinism
+∞
10.4
10
*
R4120
NOMESCO Finland
Occupational therapy
2.8
10.3
55
212
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.6
10.3
65
273
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
13.4
10.2
17
13
SPAT1216
SPAT
Assessment of functional ability
2.3
10.1
82
387
G91.1
ICD-10 Finland
Obstructive hydrocephalus
14.9
10.0
16
11
L04AA31
ATC
[U] teriflunomide
40.8
10.0
12
*
L04AA27
ATC
[U] fingolimod
40.8
10.0
12
*
F83
ICD-10 Finland
Mixed specific developmental disorders
5.3
9.9
20
39
R5110, ,
SPAT
2.7
9.9
55
217
353
Kela drug reimbursment
Cladribine and fingolimod
26.5
9.8
13
5
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
9.8
138
803
H54.7
ICD-10 Finland
Unspecified visual loss
13.7
9.7
16
12
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
11.6
9.6
17
15
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.3
9.6
79
375
XF400
NOMESCO Finland
ECG with 12 standard connections
2.1
9.5
97
501
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
4.2
9.5
25
61
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.7
9.5
55
221
DFF59
NOMESCO Finland
Other assessment of balance
12.6
9.4
16
13
N04BB01
ATC
amantadine; oral
9.7
9.3
18
19
R13
ICD-10 Finland
Dysphagia
2.7
9.3
50
194
XCD10
NOMESCO Finland
Electrophysiological examination of eye
4.5
9.2
22
50
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.1
9.1
97
509
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
2.9
9.1
44
161
A06AD11
ATC
lactulose; oral
2.3
9.1
72
336
R4110
NOMESCO Finland
Physiotherapy
1.8
9.0
166
1052
N03AX11
ATC
topiramate; oral
3.9
8.9
26
69
WX408
NOMESCO Finland
General anesthesy, balanced
1.8
8.6
151
941
N05CD08
ATC
midazolam; nasal, systemic
4.3
8.5
22
53
H50.8
ICD-10 Finland
Other specified strabismus
28.0
8.5
11
*
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.3
8.5
67
312
R1260
NOMESCO Finland
Evaluation of communicative skills
5.0
8.4
18
37
RS221, ,
NOMESCO Finland
4.8
8.4
19
41
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.1
8.3
92
489
183
Kela drug reimbursment
Lamotrigin and topiramate
7.2
8.3
19
27
AA1BD
NOMESCO Finland
Extensive CT of head and brain
4.5
8.2
20
46
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
8.2
167
1085
Z3226
NOMESCO Finland
Physiotherapist
1.9
8.2
115
666
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
2.8
8.1
42
160
AA7AA
NOMESCO Finland
Liquor cerebri shunt X-ray examinatin without contrast
22.4
8.0
11
5
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
3.7
7.9
25
70
Z31.5
ICD-10 Finland
Genetic counselling
2.5
7.9
50
210
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.3
7.9
62
288
H50.2
ICD-10 Finland
Vertical strabismus
8.6
7.9
16
19
H46
ICD-10 Finland
Optic neuritis
8.6
7.9
16
19
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.3
7.8
59
269
Z3231
NOMESCO Finland
Registered nurse
1.8
7.8
163
1064
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.0
7.8
87
464
ZXA10
NOMESCO Finland
Bilateral
1.9
7.8
104
591
H53.9
ICD-10 Finland
Visual disturbance, unspecified
3.3
7.8
29
91
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
15.3
7.7
12
8
CE2W4
NOMESCO Finland
Eye movement mapping
45.6
7.7
9
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
8.2
7.6
16
20
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.3
7.6
59
272
G81.9
ICD-10 Finland
Hemiplegia, unspecified
9.0
7.6
15
17
R56.8
ICD-10 Finland
Other and unspecified convulsions
2.7
7.5
41
160
R51.80
ICD-10 Finland
Headache
1.9
7.5
107
622
UKC02
NOMESCO Finland
Cystoscopy
2.1
7.4
74
378
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
81.1
7.4
8
*
G11.9
ICD-10 Finland
Hereditary ataxia, unspecified
81.1
7.4
8
*
P85
ICPC
Mental retardation
13.6
7.4
12
9
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.2
7.4
29
94
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
7.0
7.3
17
25
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
11.1
7.3
13
12
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
9.5
7.3
14
15
G11.2
ICD-10 Finland
Late-onset cerebellar ataxia
+∞
7.3
7
*
H53.5
ICD-10 Finland
Colour vision deficiencies
+∞
7.3
7
*
N06AX11
ATC
mirtazapine; oral
1.7
7.3
184
1262
H81.4
ICD-10 Finland
Vertigo of central origin
16.0
7.2
11
7
DFF00
NOMESCO Finland
Pure tone audiometry
2.3
7.2
58
272
R3120
NOMESCO Finland
Training in mobility skills
20.3
7.2
10
5
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
4.1
7.1
19
47
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.0
7.1
84
458
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
10.2
7.1
13
13
S06.0
ICD-10 Finland
Concussion
2.0
6.9
73
382
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.6
6.9
208
1490
CS494
NOMESCO Finland
Other visual field testing
3.9
6.9
20
53
37300
ICD-8 Finland
Strabismus, Concomitans convergens
9.5
6.8
13
14
H51.9
ICD-10 Finland
Disorder of binocular movement, unspecified
40.5
6.8
8
*
74439
ICD-8 Finland
Congenital anomalies of eye, Cataracta NUD
40.5
6.8
8
*
ZXA05
NOMESCO Finland
Left side
1.8
6.7
117
722
205
Kela drug reimbursment
Chronic hypertension
1.8
6.7
106
635
K02.1
ICD-10 Finland
Caries of dentine
1.6
6.7
345
2801
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.7
6.6
146
961
Z01.1
ICD-10 Finland
Examination of ears and hearing
1.9
6.6
83
461
WX110
NOMESCO Finland
Infiltration anesthesia
1.7
6.6
407
3448
R47.1
ICD-10 Finland
Dysarthria and anarthria
10.2
6.6
12
12
WX002
NOMESCO Finland
Sedation and analgesia
1.8
6.6
99
584
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
7.0
6.5
15
22
N07CA01
ATC
betahistine; oral
2.5
6.5
40
166
N02BF01
ATC
gabapentin; oral
2.1
6.5
60
298
SPAT1301
SPAT
No procedures
1.7
6.4
164
1121
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
7.5
6.4
14
19
7433A
ICD-9 Finland
Congenital anomalies of eye, Congenital cataract and lens anomalies
70.6
6.4
7
*
SPAT1234
SPAT
Support of social functional capacity
3.0
6.4
28
97
XCK10
NOMESCO Finland
Photography of fundus of eye
2.3
6.4
50
232
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
2.3
6.4
46
206
ZXA00
NOMESCO Finland
Right side
1.7
6.4
130
838
WX140
NOMESCO Finland
Parabulbar anesthesy
2.9
6.4
29
103
SFA10
NOMESCO Finland
One-surface restoration
1.6
6.3
313
2502
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
11.2
6.3
11
10
ZX120
NOMESCO Finland
Intravenous
2.2
6.3
56
274
G44.2
ICD-10 Finland
Tension-type headache
1.9
6.3
83
469
N05AH04
ATC
quetiapine; oral
1.8
6.3
110
679
7423A
ICD-9 Finland
Other congenital anomalies of nervous system, Congenital hydrocephalus
+∞
6.3
6
*
G04BD09
ATC
trospium; oral
5.1
6.2
18
36
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.7
6.2
132
859
H53.4
ICD-10 Finland
Visual field defects
4.0
6.2
17
43
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
6.4
6.2
15
24
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
5.4
6.2
17
32
H81.9
ICD-10 Finland
Disorder of vestibular function, unspecified
7.8
6.1
13
17
ZXE10
NOMESCO Finland
More than one and less than three hours
1.6
6.1
183
1300
-45
ICPC
Observ/health educat/advice/diet
3.5
6.1
20
58
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
3.5
6.1
20
58
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
6.1
6.0
15
25

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
1.4e+00
2.3e+00
2.9e+00
—
3.3e+00
2.9e+00
2.0e+00
cases:27.71%
controls:8.67%
cases:28.79%
controls:3.76%
cases:11.71%
controls:0.69%
—
—
cases:20.04%
controls:0.89%
cases:42.23%
controls:3.75%
cases:42.21%
controls:8.87%
143
445
373
4689
150
195
371
4985
61
36
460
5144
—
104
46
415
5130
212
188
290
4829
187
392
256
4025
Multiple sclerosis
G35 [45571794]
2.3e+00
2.7e+00
3.2e+00
1.0e+50
—
3.2e+00
3.1e+00
cases:4.07%
controls:0.41%
cases:5.57%
controls:0.39%
cases:2.69%
controls:0.12%
cases:2.50%
controls:0.00%
—
—
cases:8.76%
controls:0.38%
cases:8.80%
controls:0.43%
21
21
495
5113
29
20
492
5160
14
6
507
5174
13
0
508
5180
—
44
19
458
4998
39
19
404
4398
Dizziness and giddiness
R42 [45568132]
1.4e+00
2.5e+00
—
1.0e+50
4.2e+00
2.8e+00
1.3e+00
cases:9.11%
controls:2.38%
cases:8.25%
controls:0.73%
—
—
cases:10.17%
controls:0.00%
cases:5.97%
controls:0.10%
cases:8.76%
controls:0.60%
cases:10.38%
controls:2.99%
47
122
469
5012
43
38
478
5142
—
53
0
468
5180
31
5
488
5171
44
30
458
4987
46
132
397
4285
Outpatient Visit
OP [9202]
4.8e-01
7.7e-01
8.8e-01
5.2e+00
1.5e+00
1.3e+00
1.1e+00
cases:77.33%
controls:67.90%
cases:66.22%
controls:47.63%
cases:23.61%
controls:11.37%
cases:48.94%
controls:0.52%
cases:34.68%
controls:10.68%
cases:77.29%
controls:48.28%
cases:90.97%
controls:76.95%
399
3486
117
1648
345
2467
176
2713
123
589
398
4591
255
27
266
5153
180
553
339
4623
388
2422
114
2595
403
3399
40
1018
Inpatient Hospital
21 [8717]
5.0e-01
1.0e+00
1.6e+00
4.7e+00
1.8e+00
9.1e-01
6.5e-01
cases:42.05%
controls:30.54%
cases:23.22%
controls:9.94%
cases:6.53%
controls:1.39%
cases:9.60%
controls:0.10%
cases:8.29%
controls:1.41%
cases:19.92%
controls:9.07%
cases:36.57%
controls:23.21%
217
1568
299
3566
121
515
400
4665
34
72
487
5108
50
5
471
5175
43
73
476
5103
100
455
402
4562
162
1025
281
3392
Neurosurgery
14 [38004459]
1.0e+00
1.7e+00
2.3e+00
—
2.2e+00
2.0e+00
1.5e+00
cases:5.04%
controls:1.83%
cases:4.61%
controls:0.87%
cases:1.92%
controls:0.19%
—
—
cases:1.54%
controls:0.17%
cases:4.98%
controls:0.74%
cases:8.80%
controls:2.17%
26
94
490
5040
24
45
497
5135
10
10
511
5170
—
8
9
511
5167
25
37
477
4980
39
96
404
4321
Ophthalmology
18 [38004463]
8.6e-01
1.2e+00
1.7e+00
—
3.1e+00
2.1e+00
1.3e+00
cases:27.33%
controls:13.77%
cases:19.58%
controls:6.72%
cases:6.33%
controls:1.18%
—
—
cases:15.61%
controls:0.85%
cases:37.05%
controls:6.66%
cases:41.53%
controls:16.12%
141
707
375
4427
102
348
419
4832
33
61
488
5119
—
81
44
438
5132
186
334
316
4683
184
712
259
3705
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
8.7e-01
1.3e+00
2.5e+00
1.0e+50
3.0e+00
1.5e+00
7.8e-01
cases:9.30%
controls:4.13%
cases:5.95%
controls:1.76%
cases:2.69%
controls:0.23%
cases:5.95%
controls:0.00%
cases:4.24%
controls:0.21%
cases:6.77%
controls:1.65%
cases:11.96%
controls:5.84%
48
212
468
4922
31
91
490
5089
14
12
507
5168
31
0
490
5180
22
11
497
5165
34
83
468
4934
53
258
390
4159
clobazam; oral
N05BA09 [21604574]
2.3e+00
2.5e+00
—
—
—
2.2e+00
2.6e+00
cases:1.16%
controls:0.12%
cases:1.15%
controls:0.10%
—
—
—
—
—
—
cases:1.39%
controls:0.16%
cases:2.03%
controls:0.16%
6
6
510
5128
6
5
515
5175
—
—
—
7
8
495
5009
9
7
434
4410
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
1.5e+00
2.4e+00
—
1.0e+50
—
3.2e+00
2.2e+00
cases:3.68%
controls:0.82%
cases:4.22%
controls:0.39%
—
—
cases:1.92%
controls:0.00%
—
—
cases:5.78%
controls:0.26%
cases:8.35%
controls:1.02%
19
42
497
5092
22
20
499
5160
—
10
0
511
5180
—
29
13
473
5004
37
45
406
4372
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
2.4e+00
1.9e+00
—
—
—
2.7e+00
2.1e+00
cases:1.94%
controls:0.18%
cases:1.54%
controls:0.23%
—
—
—
—
—
—
cases:1.99%
controls:0.14%
cases:2.26%
controls:0.27%
10
9
506
5125
8
12
513
5168
—
—
—
10
7
492
5010
10
12
433
4405
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.7e-01
5.8e-01
1.2e+00
4.8e+00
1.5e+00
7.2e-01
3.7e-01
cases:31.01%
controls:25.56%
cases:26.49%
controls:16.72%
cases:9.40%
controls:3.11%
cases:12.48%
controls:0.12%
cases:12.91%
controls:3.28%
cases:28.09%
controls:15.95%
cases:44.70%
controls:35.82%
160
1312
356
3822
138
866
383
4314
49
161
472
5019
65
6
456
5174
67
170
452
5006
141
800
361
4217
198
1582
245
2835
Emergency Medicine
93 [38004510]
3.3e-01
8.0e-01
1.6e+00
4.8e+00
1.1e+00
7.0e-01
2.7e-01
cases:15.31%
controls:11.53%
cases:13.63%
controls:6.62%
cases:5.57%
controls:1.12%
cases:10.36%
controls:0.10%
cases:2.70%
controls:0.95%
cases:12.95%
controls:6.88%
cases:24.15%
controls:19.56%
79
592
437
4542
71
343
450
4837
29
58
492
5122
54
5
467
5175
14
49
505
5127
65
345
437
4672
107
864
336
3553
Psychologist
Z2445 [2001311558]
1.3e+00
1.9e+00
—
—
—
2.8e+00
2.6e+00
cases:2.33%
controls:0.66%
cases:1.54%
controls:0.23%
—
—
—
—
—
—
cases:1.99%
controls:0.12%
cases:2.48%
controls:0.18%
12
34
504
5100
8
12
513
5168
—
—
—
10
6
492
5011
11
8
432
4409
levetiracetam; oral, parenteral
N03AX14 [21604436]
2.3e+00
2.0e+00
—
—
—
2.1e+00
1.8e+00
cases:2.91%
controls:0.29%
cases:2.30%
controls:0.31%
—
—
—
—
—
—
cases:1.99%
controls:0.24%
cases:2.26%
controls:0.36%
15
15
501
5119
12
16
509
5164
—
—
—
10
12
492
5005
10
16
433
4401
baclofen; oral, parenteral
M03BX01 [21604115]
1.7e+00
2.4e+00
—
—
—
3.2e+00
2.7e+00
cases:1.16%
controls:0.21%
cases:1.54%
controls:0.14%
—
—
—
—
—
—
cases:2.39%
controls:0.10%
cases:2.93%
controls:0.20%
6
11
510
5123
8
7
513
5173
—
—
—
12
5
490
5012
13
9
430
4408
Physiotherapy
R4110 [2001310233]
6.8e-01
1.3e+00
1.8e+00
1.0e+50
2.2e+00
1.5e+00
8.2e-01
cases:8.14%
controls:4.30%
cases:6.14%
controls:1.83%
cases:1.54%
controls:0.25%
cases:1.15%
controls:0.00%
cases:2.31%
controls:0.25%
cases:6.97%
controls:1.65%
cases:9.03%
controls:4.19%
42
221
474
4913
32
95
489
5085
8
13
513
5167
6
0
515
5180
12
13
507
5163
35
83
467
4934
40
185
403
4232
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
1.2e+00
2.5e+00
—
1.0e+50
—
2.6e+00
1.9e+00
cases:3.29%
controls:1.05%
cases:3.45%
controls:0.29%
—
—
cases:3.45%
controls:0.00%
—
—
cases:3.98%
controls:0.30%
cases:6.09%
controls:1.00%
17
54
499
5080
18
15
503
5165
—
18
0
503
5180
—
20
15
482
5002
27
44
416
4373
oxcarbazepine; oral
N03AF02 [21604418]
2.0e+00
2.1e+00
—
—
—
1.9e+00
2.0e+00
cases:3.68%
controls:0.51%
cases:2.69%
controls:0.35%
—
—
—
—
—
—
cases:2.99%
controls:0.44%
cases:4.06%
controls:0.54%
19
26
497
5108
14
18
507
5162
—
—
—
15
22
487
4995
18
24
425
4393
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.8e-01
5.3e-01
1.0e+00
4.0e+00
1.3e+00
5.3e-01
4.2e-01
cases:32.95%
controls:27.00%
cases:30.71%
controls:20.68%
cases:10.36%
controls:4.03%
cases:12.48%
controls:0.27%
cases:13.68%
controls:4.10%
cases:30.28%
controls:20.33%
cases:48.76%
controls:38.35%
170
1386
346
3748
160
1071
361
4109
54
209
467
4971
65
14
456
5166
71
212
448
4964
152
1020
350
3997
216
1694
227
2723
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.8e-01
5.0e-01
1.0e+00
3.9e+00
1.3e+00
5.1e-01
4.3e-01
cases:33.14%
controls:27.25%
cases:30.52%
controls:21.04%
cases:10.75%
controls:4.15%
cases:12.28%
controls:0.27%
cases:13.68%
controls:4.15%
cases:30.08%
controls:20.45%
cases:48.98%
controls:38.49%
171
1399
345
3735
159
1090
362
4090
56
215
465
4965
64
14
457
5166
71
215
448
4961
151
1026
351
3991
217
1700
226
2717
Examination of eyes and vision
Z01.0 [45566391]
4.5e-01
1.1e+00
2.2e+00
—
3.0e+00
1.4e+00
5.7e-01
cases:4.26%
controls:2.77%
cases:3.07%
controls:1.02%
cases:1.15%
controls:0.14%
—
—
cases:2.31%
controls:0.12%
cases:4.38%
controls:1.10%
cases:6.09%
controls:3.53%
22
142
494
4992
16
53
505
5127
6
7
515
5173
—
12
6
507
5170
22
55
480
4962
27
156
416
4261
INR in Blood by Coagulation assay
34714-6 [3032080]
1.7e-01
5.0e-01
9.7e-01
4.0e+00
1.4e+00
7.4e-01
5.1e-01
cases:10.08%
controls:8.63%
cases:7.87%
controls:4.90%
cases:3.84%
controls:1.49%
cases:6.91%
controls:0.14%
cases:5.59%
controls:1.41%
cases:8.17%
controls:4.09%
cases:14.00%
controls:8.90%
52
443
464
4691
41
254
480
4926
20
77
501
5103
36
7
485
5173
29
73
490
5103
41
205
461
4812
62
393
381
4024
Otolaryngology
4 [38004449]
5.0e-01
7.9e-01
1.5e+00
1.0e+50
2.5e+00
1.4e+00
6.3e-01
cases:15.89%
controls:10.28%
cases:8.83%
controls:4.23%
cases:3.65%
controls:0.81%
cases:4.22%
controls:0.00%
cases:6.94%
controls:0.60%
cases:13.94%
controls:3.99%
cases:19.19%
controls:11.21%
82
528
434
4606
46
219
475
4961
19
42
502
5138
22
0
499
5180
36
31
483
5145
70
200
432
4817
85
495
358
3922
CBC panel - Blood by Automated count
58410-2 [40761511]
2.4e-01
4.6e-01
1.0e+00
3.9e+00
1.4e+00
5.0e-01
3.1e-01
cases:33.33%
controls:28.15%
cases:26.49%
controls:18.49%
cases:8.45%
controls:3.17%
cases:9.60%
controls:0.21%
cases:12.72%
controls:3.46%
cases:26.49%
controls:17.98%
cases:45.37%
controls:37.97%
172
1445
344
3689
138
958
383
4222
44
164
477
5016
50
11
471
5169
66
179
453
4997
133
902
369
4115
201
1677
242
2740
clonazepam; oral, parenteral
N03AE01 [21604415]
1.2e+00
1.7e+00
2.2e+00
—
—
1.8e+00
1.6e+00
cases:2.13%
controls:0.62%
cases:2.88%
controls:0.52%
cases:1.15%
controls:0.14%
—
—
—
—
cases:3.39%
controls:0.56%
cases:4.29%
controls:0.91%
11
32
505
5102
15
27
506
5153
6
7
515
5173
—
—
17
28
485
4989
19
40
424
4377
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.4e-01
4.4e-01
9.4e-01
3.8e+00
1.2e+00
4.3e-01
3.8e-01
cases:34.69%
controls:29.57%
cases:32.82%
controls:23.88%
cases:11.52%
controls:4.83%
cases:12.48%
controls:0.31%
cases:15.41%
controls:5.16%
cases:32.27%
controls:23.72%
cases:51.69%
controls:42.25%
179
1518
337
3616
171
1237
350
3943
60
250
461
4930
65
16
456
5164
80
267
439
4909
162
1190
340
3827
229
1866
214
2551
Office Visit
OMOP4822458 [581477]
6.7e-01
8.2e-01
1.5e+00
1.0e+50
2.2e+00
9.7e-01
8.9e-01
cases:16.86%
controls:9.37%
cases:7.87%
controls:3.61%
cases:2.30%
controls:0.50%
cases:4.80%
controls:0.00%
cases:5.39%
controls:0.62%
cases:8.37%
controls:3.35%
cases:16.25%
controls:7.36%
87
481
429
4653
41
187
480
4993
12
26
509
5154
25
0
496
5180
28
32
491
5144
42
168
460
4849
72
325
371
4092
Cerebral infarction, unspecified
I63.9 [45596216]
1.1e+00
2.1e+00
—
—
—
2.1e+00
1.6e+00
cases:2.71%
controls:0.88%
cases:1.92%
controls:0.25%
—
—
—
—
—
—
cases:2.99%
controls:0.38%
cases:3.61%
controls:0.77%
14
45
502
5089
10
13
511
5167
—
—
—
15
19
487
4998
16
34
427
4383
Physical Medicine And Rehabilitation
25 [38004468]
8.0e-01
9.7e-01
1.9e+00
—
1.4e+00
9.7e-01
7.5e-01
cases:11.63%
controls:5.57%
cases:6.14%
controls:2.43%
cases:2.30%
controls:0.35%
—
—
cases:1.93%
controls:0.46%
cases:6.37%
controls:2.51%
cases:13.32%
controls:6.77%
60
286
456
4848
32
126
489
5054
12
18
509
5162
—
10
24
509
5152
32
126
470
4891
59
299
384
4118
Neuropsychological investigation
XA800 [2001300412]
1.5e+00
—
—
—
—
3.1e+00
2.1e+00
cases:2.13%
controls:0.47%
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.12%
cases:3.16%
controls:0.41%
11
24
505
5110
—
—
—
—
13
6
489
5011
14
18
429
4399
Audiology
64 [38004489]
4.8e-01
9.8e-01
2.2e+00
—
2.2e+00
1.3e+00
7.5e-01
cases:3.88%
controls:2.43%
cases:3.07%
controls:1.18%
cases:1.34%
controls:0.15%
—
—
cases:2.31%
controls:0.25%
cases:4.38%
controls:1.22%
cases:5.64%
controls:2.74%
20
125
496
5009
16
61
505
5119
7
8
514
5172
—
12
13
507
5163
22
61
480
4956
25
121
418
4296
lamotrigine; oral
N03AX09 [21604431]
1.4e+00
1.6e+00
—
—
—
1.9e+00
1.7e+00
cases:2.33%
controls:0.58%
cases:1.54%
controls:0.31%
—
—
—
—
—
—
cases:1.79%
controls:0.28%
cases:3.61%
controls:0.70%
12
30
504
5104
8
16
513
5164
—
—
—
9
14
493
5003
16
31
427
4386
Emergency Room Visit
ER [9203]
5.5e-01
9.8e-01
1.8e+00
—
1.5e+00
9.1e-01
6.9e-01
cases:45.74%
controls:32.68%
cases:26.68%
controls:12.03%
cases:8.83%
controls:1.51%
—
—
cases:6.36%
controls:1.47%
cases:22.51%
controls:10.46%
cases:44.47%
controls:28.73%
236
1678
280
3456
139
623
382
4557
46
78
475
5102
—
33
76
486
5100
113
525
389
4492
197
1269
246
3148
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.8e-01
3.5e-01
8.8e-01
3.6e+00
1.2e+00
4.3e-01
2.5e-01
cases:37.98%
controls:33.76%
cases:35.12%
controls:27.59%
cases:13.05%
controls:5.89%
cases:12.86%
controls:0.39%
cases:17.92%
controls:6.30%
cases:36.65%
controls:27.43%
cases:54.63%
controls:48.43%
196
1733
320
3401
183
1429
338
3751
68
305
453
4875
67
20
454
5160
93
326
426
4850
184
1376
318
3641
242
2139
201
2278
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.8e-01
3.6e-01
8.7e-01
3.6e+00
1.2e+00
4.2e-01
2.6e-01
cases:37.98%
controls:33.79%
cases:35.32%
controls:27.63%
cases:13.05%
controls:5.91%
cases:12.86%
controls:0.39%
cases:17.92%
controls:6.32%
cases:36.65%
controls:27.53%
cases:54.85%
controls:48.47%
196
1735
320
3399
184
1431
337
3749
68
306
453
4874
67
20
454
5160
93
327
426
4849
184
1381
318
3636
243
2141
200
2276
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.8e-01
3.6e-01
8.7e-01
3.6e+00
1.2e+00
4.2e-01
2.6e-01
cases:37.98%
controls:33.77%
cases:35.32%
controls:27.57%
cases:13.05%
controls:5.93%
cases:12.86%
controls:0.39%
cases:17.92%
controls:6.32%
cases:36.65%
controls:27.53%
cases:54.85%
controls:48.43%
196
1734
320
3400
184
1428
337
3752
68
307
453
4873
67
20
454
5160
93
327
426
4849
184
1381
318
3636
243
2139
200
2278
Platelets [#/volume] in Blood
26515-7 [3007461]
1.8e-01
3.6e-01
8.8e-01
3.6e+00
1.2e+00
4.2e-01
2.5e-01
cases:37.79%
controls:33.74%
cases:35.12%
controls:27.45%
cases:13.05%
controls:5.89%
cases:12.86%
controls:0.39%
cases:17.73%
controls:6.28%
cases:36.65%
controls:27.49%
cases:54.63%
controls:48.31%
195
1732
321
3402
183
1422
338
3758
68
305
453
4875
67
20
454
5160
92
325
427
4851
184
1379
318
3638
242
2134
201
2283
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.8e-01
3.6e-01
8.7e-01
3.6e+00
1.2e+00
4.2e-01
2.6e-01
cases:37.98%
controls:33.81%
cases:35.32%
controls:27.66%
cases:13.05%
controls:5.93%
cases:12.86%
controls:0.39%
cases:17.92%
controls:6.30%
cases:36.65%
controls:27.55%
cases:54.85%
controls:48.47%
196
1736
320
3398
184
1433
337
3747
68
307
453
4873
67
20
454
5160
93
326
426
4850
184
1382
318
3635
243
2141
200
2276
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.8e-01
3.5e-01
8.8e-01
3.6e+00
1.2e+00
4.1e-01
2.6e-01
cases:37.98%
controls:33.77%
cases:35.12%
controls:27.57%
cases:13.05%
controls:5.89%
cases:12.86%
controls:0.39%
cases:17.92%
controls:6.30%
cases:36.45%
controls:27.51%
cases:54.85%
controls:48.43%
196
1734
320
3400
183
1428
338
3752
68
305
453
4875
67
20
454
5160
93
326
426
4850
183
1380
319
3637
243
2139
200
2278
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
1.1e+00
1.5e+00
—
—
—
2.1e+00
1.7e+00
cases:2.71%
controls:0.93%
cases:2.30%
controls:0.50%
—
—
—
—
—
—
cases:2.39%
controls:0.30%
cases:4.29%
controls:0.79%
14
48
502
5086
12
26
509
5154
—
—
—
12
15
490
5002
19
35
424
4382
MCH [Entitic mass]
28539-5 [3035941]
1.8e-01
3.4e-01
8.8e-01
3.6e+00
1.2e+00
4.0e-01
2.6e-01
cases:37.98%
controls:33.77%
cases:34.93%
controls:27.55%
cases:13.05%
controls:5.89%
cases:12.86%
controls:0.39%
cases:17.92%
controls:6.30%
cases:36.25%
controls:27.51%
cases:54.85%
controls:48.40%
196
1734
320
3400
182
1427
339
3753
68
305
453
4875
67
20
454
5160
93
326
426
4850
182
1380
320
3637
243
2138
200
2279
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
5.8e-01
1.8e+00
—
1.0e+50
—
3.0e+00
1.6e+00
cases:1.94%
controls:1.09%
cases:1.73%
controls:0.29%
—
—
cases:1.34%
controls:0.00%
—
—
cases:2.99%
controls:0.16%
cases:3.84%
controls:0.79%
10
56
506
5078
9
15
512
5165
—
7
0
514
5180
—
15
8
487
5009
17
35
426
4382
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
9.6e-02
3.7e-01
8.5e-01
3.5e+00
1.1e+00
4.4e-01
3.1e-01
cases:23.84%
controls:22.15%
cases:24.18%
controls:18.03%
cases:8.83%
controls:3.98%
cases:8.06%
controls:0.27%
cases:11.75%
controls:4.19%
cases:25.10%
controls:17.70%
cases:39.50%
controls:32.44%
123
1137
393
3997
126
934
395
4246
46
206
475
4974
42
14
479
5166
61
217
458
4959
126
888
376
4129
175
1433
268
2984
gabapentin; oral
N02BF01 [955005]
6.0e-01
1.6e+00
1.3e+00
—
1.8e+00
1.7e+00
1.1e+00
cases:3.68%
controls:2.06%
cases:4.61%
controls:0.95%
cases:1.34%
controls:0.37%
—
—
cases:2.31%
controls:0.41%
cases:5.98%
controls:1.18%
cases:8.80%
controls:3.17%
19
106
497
5028
24
49
497
5131
7
19
514
5161
—
12
21
507
5155
30
59
472
4958
39
140
404
4277
Other healthcare associate professional
Z3229 [2001311561]
1.3e+00
1.6e+00
—
1.0e+50
—
2.1e+00
1.1e+00
cases:3.10%
controls:0.86%
cases:1.54%
controls:0.31%
—
—
cases:1.54%
controls:0.00%
—
—
cases:2.19%
controls:0.28%
cases:3.39%
controls:1.13%
16
44
500
5090
8
16
513
5164
—
8
0
513
5180
—
11
14
491
5003
15
50
428
4367
Epilepsy, unspecified
G40.9 [45562083]
2.1e+00
1.7e+00
—
—
—
2.2e+00
1.8e+00
cases:2.71%
controls:0.33%
cases:1.15%
controls:0.21%
—
—
—
—
—
—
cases:1.39%
controls:0.16%
cases:2.71%
controls:0.48%
14
17
502
5117
6
11
515
5169
—
—
—
7
8
495
5009
12
21
431
4396
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.9e-01
3.7e-01
6.8e-01
2.9e+00
1.2e+00
4.8e-01
3.5e-01
cases:34.69%
controls:28.46%
cases:28.21%
controls:21.41%
cases:7.49%
controls:3.94%
cases:2.50%
controls:0.14%
cases:12.52%
controls:4.00%
cases:29.88%
controls:20.87%
cases:49.44%
controls:40.84%
179
1461
337
3673
147
1109
374
4071
39
204
482
4976
13
7
508
5173
65
207
454
4969
150
1047
352
3970
219
1804
224
2613
Outpatient Hospital
22 [8756]
5.2e-01
1.0e+00
1.4e+00
—
1.6e+00
9.0e-01
5.3e-01
cases:34.30%
controls:23.65%
cases:17.66%
controls:7.12%
cases:4.03%
controls:1.00%
—
—
cases:4.43%
controls:0.97%
cases:14.74%
controls:6.54%
cases:25.96%
controls:17.16%
177
1214
339
3920
92
369
429
4811
21
52
500
5128
—
23
50
496
5126
74
328
428
4689
115
758
328
3659
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.1e-01
4.1e-01
9.0e-01
3.5e+00
9.4e-01
2.9e-01
3.3e-01
cases:24.03%
controls:20.45%
cases:23.42%
controls:16.87%
cases:8.25%
controls:3.53%
cases:7.49%
controls:0.23%
cases:9.06%
controls:3.73%
cases:21.51%
controls:17.04%
cases:37.25%
controls:29.91%
124
1050
392
4084
122
874
399
4306
43
183
478
4997
39
12
482
5168
47
193
472
4983
108
855
394
4162
165
1321
278
3096
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
1.4e+00
1.5e+00
—
—
—
1.5e+00
1.3e+00
cases:3.88%
controls:0.95%
cases:3.45%
controls:0.83%
—
—
—
—
—
—
cases:3.59%
controls:0.80%
cases:4.06%
controls:1.09%
20
49
496
5085
18
43
503
5137
—
—
—
18
40
484
4977
18
48
425
4369
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
5.1e-01
8.6e-01
1.2e+00
—
1.8e+00
7.3e-01
6.5e-01
cases:12.79%
controls:8.08%
cases:9.60%
controls:4.31%
cases:2.69%
controls:0.79%
—
—
cases:3.47%
controls:0.62%
cases:7.77%
controls:3.91%
cases:16.93%
controls:9.64%
66
415
450
4719
50
223
471
4957
14
41
507
5139
—
18
32
501
5144
39
196
463
4821
75
426
368
3991
Social worker
Z2446 [2001311559]
1.3e+00
—
—
—
—
2.3e+00
2.1e+00
cases:2.91%
controls:0.80%
—
—
—
—
—
—
—
—
cases:1.39%
controls:0.14%
cases:3.61%
controls:0.48%
15
41
501
5093
—
—
—
—
7
7
495
5010
16
21
427
4396
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]
1.0e+00
2.6e+00
—
—
—
3.0e+00
1.3e+00
cases:1.36%
controls:0.49%
cases:1.73%
controls:0.14%
—
—
—
—
—
—
cases:1.99%
controls:0.10%
cases:1.58%
controls:0.43%
7
25
509
5109
9
7
512
5173
—
—
—
10
5
492
5012
7
19
436
4398
Paediatric neurology
421 [44777781]
1.2e+00
1.5e+00
1.1e+00
1.0e+50
1.6e+00
1.5e+00
1.4e+00
cases:3.49%
controls:1.11%
cases:4.22%
controls:0.95%
cases:0.96%
controls:0.31%
cases:1.15%
controls:0.00%
cases:1.16%
controls:0.23%
cases:4.38%
controls:1.06%
cases:5.42%
controls:1.38%
18
57
498
5077
22
49
499
5131
5
16
516
5164
6
0
515
5180
6
12
513
5164
22
53
480
4964
24
61
419
4356
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
3.2e-01
7.5e-01
1.5e+00
—
1.8e+00
9.0e-01
5.6e-01
cases:14.73%
controls:11.10%
cases:11.71%
controls:5.89%
cases:4.03%
controls:0.97%
—
—
cases:4.62%
controls:0.79%
cases:10.96%
controls:4.74%
cases:22.12%
controls:14.01%
76
570
440
4564
61
305
460
4875
21
50
500
5130
—
24
41
495
5135
55
238
447
4779
98
619
345
3798
Thorax X-ray examination
GD1AA [2001303617]
6.4e-01
9.0e-01
2.0e+00
1.0e+50
1.6e+00
1.2e+00
7.6e-01
cases:12.98%
controls:7.28%
cases:6.53%
controls:2.76%
cases:2.11%
controls:0.29%
cases:3.65%
controls:0.00%
cases:1.16%
controls:0.23%
cases:6.77%
controls:2.21%
cases:14.22%
controls:7.22%
67
374
449
4760
34
143
487
5037
11
15
510
5165
19
0
502
5180
6
12
513
5164
34
111
468
4906
63
319
380
4098
Cell count panel - Cerebral spinal fluid
34563-7 [3044290]
1.2e+00
2.5e+00
—
—
—
2.9e+00
1.4e+00
cases:1.36%
controls:0.41%
cases:1.92%
controls:0.15%
—
—
—
—
—
—
cases:1.79%
controls:0.10%
cases:1.58%
controls:0.38%
7
21
509
5113
10
8
511
5172
—
—
—
9
5
493
5012
7
17
436
4400
General Practice
1 [38004446]
3.2e-01
8.2e-01
1.4e+00
1.0e+50
1.5e+00
7.7e-01
8.3e-01
cases:14.73%
controls:11.14%
cases:9.21%
controls:4.27%
cases:2.30%
controls:0.60%
cases:2.30%
controls:0.00%
cases:3.66%
controls:0.81%
cases:8.76%
controls:4.27%
cases:23.25%
controls:11.64%
76
572
440
4562
48
221
473
4959
12
31
509
5149
12
0
509
5180
19
42
500
5134
44
214
458
4803
103
514
340
3903
Diplopia
H53.2 [45576792]
2.7e+00
—
1.0e+50
1.0e+50
1.0e+50
—
2.4e+00
cases:2.91%
controls:0.19%
—
—
cases:1.34%
controls:0.00%
cases:3.84%
controls:0.00%
cases:1.93%
controls:0.00%
—
—
cases:2.48%
controls:0.23%
15
10
501
5124
—
7
0
514
5180
20
0
501
5180
10
0
509
5176
—
11
10
432
4407
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
8.5e-01
7.4e-01
2.3e+00
—
2.1e+00
1.7e+00
1.2e+00
cases:3.29%
controls:1.44%
cases:1.92%
controls:0.93%
cases:1.34%
controls:0.14%
—
—
cases:0.96%
controls:0.12%
cases:3.59%
controls:0.70%
cases:4.51%
controls:1.47%
17
74
499
5060
10
48
511
5132
7
7
514
5173
—
5
6
514
5170
18
35
484
4982
20
65
423
4352
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
5.6e-01
1.1e+00
—
1.0e+50
3.0e+00
1.1e+00
9.1e-01
cases:4.07%
controls:2.38%
cases:3.65%
controls:1.20%
—
—
cases:3.07%
controls:0.00%
cases:1.93%
controls:0.10%
cases:2.59%
controls:0.92%
cases:6.09%
controls:2.56%
21
122
495
5012
19
62
502
5118
—
16
0
505
5180
10
5
509
5171
13
46
489
4971
27
113
416
4304
Laboratory Visit
OMOP4822461 [32036]
1.3e-01
2.7e-01
7.0e-01
3.3e+00
9.8e-01
2.8e-01
1.4e-01
cases:40.70%
controls:37.59%
cases:40.88%
controls:34.61%
cases:19.00%
controls:10.46%
cases:14.01%
controls:0.60%
cases:24.08%
controls:10.65%
cases:42.03%
controls:35.42%
cases:57.79%
controls:54.24%
210
1930
306
3204
213
1793
308
3387
99
542
422
4638
73
31
448
5149
125
551
394
4625
211
1777
291
3240
256
2396
187
2021
Home Visit
OMOP4822459 [581476]
6.8e-01
8.9e-01
1.3e+00
—
1.1e+00
1.1e+00
1.0e+00
cases:7.95%
controls:4.21%
cases:5.76%
controls:2.45%
cases:3.07%
controls:0.85%
—
—
cases:2.31%
controls:0.75%
cases:8.37%
controls:3.03%
cases:16.93%
controls:6.91%
41
216
475
4918
30
127
491
5053
16
44
505
5136
—
12
39
507
5137
42
152
460
4865
75
305
368
4112
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
4.6e-03
2.4e-01
7.2e-01
3.2e+00
9.8e-01
2.6e-01
1.1e-01
cases:25.19%
controls:25.11%
cases:22.65%
controls:18.67%
cases:7.49%
controls:3.80%
cases:6.72%
controls:0.29%
cases:10.60%
controls:4.25%
cases:23.11%
controls:18.76%
cases:39.05%
controls:36.43%
130
1289
386
3845
118
967
403
4213
39
197
482
4983
35
15
486
5165
55
220
464
4956
116
941
386
4076
173
1609
270
2808
Neurological sympt/complt other
N29 [2002000734]
1.9e+00
—
—
—
—
2.9e+00
2.0e+00
cases:1.16%
controls:0.18%
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.10%
cases:1.81%
controls:0.25%
6
9
510
5125
—
—
—
—
9
5
493
5012
8
11
435
4406
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
8.5e-01
8.2e-01
1.0e+00
—
1.7e+00
1.3e+00
1.1e+00
cases:8.33%
controls:3.74%
cases:3.45%
controls:1.54%
cases:1.15%
controls:0.42%
—
—
cases:1.73%
controls:0.33%
cases:5.58%
controls:1.61%
cases:11.29%
controls:4.10%
43
192
473
4942
18
80
503
5100
6
22
515
5158
—
9
17
510
5159
28
81
474
4936
50
181
393
4236
pregabalin; oral
N02BF02 [955152]
5.4e-01
1.1e+00
1.8e+00
—
9.9e-01
9.0e-01
1.0e+00
cases:5.62%
controls:3.35%
cases:4.61%
controls:1.64%
cases:2.50%
controls:0.41%
—
—
cases:1.54%
controls:0.58%
cases:3.78%
controls:1.57%
cases:8.13%
controls:3.08%
29
172
487
4962
24
85
497
5095
13
21
508
5159
—
8
30
511
5146
19
79
483
4938
36
136
407
4281
Emergency Room and Inpatient Visit
ERIP [262]
4.3e-01
6.1e-01
1.7e+00
—
1.8e+00
7.4e-01
6.1e-01
cases:5.62%
controls:3.74%
cases:5.18%
controls:2.88%
cases:1.54%
controls:0.29%
—
—
cases:2.50%
controls:0.43%
cases:5.58%
controls:2.75%
cases:12.87%
controls:7.43%
29
192
487
4942
27
149
494
5031
8
15
513
5165
—
13
22
506
5154
28
138
474
4879
57
328
386
4089
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
3.6e-01
7.0e-01
1.8e+00
1.0e+50
2.2e+00
8.0e-01
4.5e-01
cases:8.53%
controls:6.12%
cases:5.18%
controls:2.64%
cases:2.11%
controls:0.35%
cases:6.14%
controls:0.00%
cases:4.05%
controls:0.48%
cases:5.98%
controls:2.77%
cases:11.51%
controls:7.65%
44
314
472
4820
27
137
494
5043
11
18
510
5162
32
0
489
5180
21
25
498
5151
30
139
472
4878
51
338
392
4079
Psychiatry
26 [38004469]
6.9e-01
1.0e+00
1.1e+00
—
9.7e-01
1.0e+00
9.5e-01
cases:10.08%
controls:5.32%
cases:7.10%
controls:2.66%
cases:3.26%
controls:1.14%
—
—
cases:2.89%
controls:1.12%
cases:7.57%
controls:2.83%
cases:13.77%
controls:5.84%
52
273
464
4861
37
138
484
5042
17
59
504
5121
—
15
58
504
5118
38
142
464
4875
61
258
382
4159
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
8.1e-01
1.1e+00
—
—
1.8e+00
1.1e+00
5.4e-01
cases:4.84%
controls:2.22%
cases:4.99%
controls:1.78%
—
—
—
—
cases:1.93%
controls:0.33%
cases:3.98%
controls:1.36%
cases:5.87%
controls:3.51%
25
114
491
5020
26
92
495
5088
—
—
10
17
509
5159
20
68
482
4949
26
155
417
4262
Occupational therapy
R4120 [2001310234]
1.0e+00
2.7e+00
—
—
—
2.0e+00
1.4e+00
cases:1.94%
controls:0.72%
cases:2.88%
controls:0.19%
—
—
—
—
—
—
cases:2.19%
controls:0.30%
cases:1.81%
controls:0.45%
10
37
506
5097
15
10
506
5170
—
—
—
11
15
491
5002
8
20
435
4397
Case Management Agency
251B00000X [38004193]
1.5e-01
2.3e-01
5.6e-01
3.5e+00
5.9e-01
2.5e-01
2.6e-01
cases:61.63%
controls:58.04%
cases:58.93%
controls:53.24%
cases:33.40%
controls:22.20%
cases:31.67%
controls:1.33%
cases:33.91%
controls:22.16%
cases:61.55%
controls:55.37%
cases:76.75%
controls:71.79%
318
2980
198
2154
307
2758
214
2422
174
1150
347
4030
165
69
356
5111
176
1147
343
4029
309
2778
193
2239
340
3171
103
1246
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
5.4e-02
8.3e-01
1.9e+00
—
1.9e+00
9.7e-01
5.2e-01
cases:3.10%
controls:2.94%
cases:3.65%
controls:1.62%
cases:1.34%
controls:0.21%
—
—
cases:1.35%
controls:0.21%
cases:3.98%
controls:1.55%
cases:7.00%
controls:4.30%
16
151
500
4983
19
84
502
5096
7
11
514
5169
—
7
11
512
5165
20
78
482
4939
31
190
412
4227
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
9.7e-01
1.4e+00
1.1e+00
—
—
1.2e+00
1.1e+00
cases:5.43%
controls:2.12%
cases:3.84%
controls:1.00%
cases:1.15%
controls:0.41%
—
—
—
—
cases:3.19%
controls:0.98%
cases:5.42%
controls:1.86%
28
109
488
5025
20
52
501
5128
6
21
515
5159
—
—
16
49
486
4968
24
82
419
4335
Limited function/disability (L)
L28 [2002000647]
8.7e-01
1.4e+00
-1.0e+50
—
—
1.3e+00
1.1e+00
cases:3.88%
controls:1.66%
cases:3.07%
controls:0.79%
cases:0.00%
controls:0.23%
—
—
—
—
cases:4.18%
controls:1.14%
cases:7.22%
controls:2.65%
20
85
496
5049
16
41
505
5139
0
12
521
5168
—
—
21
57
481
4960
32
117
411
4300
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
5.9e-01
8.5e-01
7.9e-01
—
1.5e+00
9.1e-01
7.7e-01
cases:15.50%
controls:9.19%
cases:11.52%
controls:5.29%
cases:2.30%
controls:1.06%
—
—
cases:3.85%
controls:0.89%
cases:11.16%
controls:4.80%
cases:21.90%
controls:11.50%
80
472
436
4662
60
274
461
4906
12
55
509
5125
—
20
46
499
5130
56
241
446
4776
97
508
346
3909
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
6.4e-01
8.6e-01
7.6e-01
—
1.3e+00
1.0e+00
7.5e-01
cases:14.53%
controls:8.22%
cases:10.36%
controls:4.65%
cases:1.92%
controls:0.91%
—
—
cases:3.08%
controls:0.83%
cases:10.36%
controls:4.09%
cases:18.51%
controls:9.71%
75
422
441
4712
54
241
467
4939
10
47
511
5133
—
16
43
503
5133
52
205
450
4812
82
429
361
3988
pH of Venous blood
2746-6 [3012544]
6.3e-01
1.4e+00
—
—
2.0e+00
1.2e+00
6.7e-01
cases:3.10%
controls:1.68%
cases:3.65%
controls:0.97%
—
—
—
—
cases:1.16%
controls:0.15%
cases:2.99%
controls:0.92%
cases:4.74%
controls:2.49%
16
86
500
5048
19
50
502
5130
—
—
6
8
513
5168
15
46
487
4971
21
110
422
4307
Headache
R51.80 [2000503603]
5.8e-01
1.4e+00
—
1.0e+50
—
1.9e+00
1.3e+00
cases:3.29%
controls:1.87%
cases:2.88%
controls:0.71%
—
—
cases:1.15%
controls:0.00%
—
—
cases:2.59%
controls:0.40%
cases:6.55%
controls:1.95%
17
96
499
5038
15
37
506
5143
—
6
0
515
5180
—
13
20
489
4997
29
86
414
4331
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
5.4e-01
1.3e+00
—
—
2.0e+00
1.2e+00
7.2e-01
cases:2.71%
controls:1.60%
cases:3.45%
controls:0.98%
—
—
—
—
cases:1.16%
controls:0.15%
cases:2.99%
controls:0.88%
cases:4.74%
controls:2.35%
14
82
502
5052
18
51
503
5129
—
—
6
8
513
5168
15
44
487
4973
21
104
422
4313
Vertigo/dizziness
N17 [2002000728]
7.0e-01
1.9e+00
—
1.0e+50
—
1.7e+00
9.3e-01
cases:2.33%
controls:1.17%
cases:1.73%
controls:0.27%
—
—
cases:0.96%
controls:0.00%
—
—
cases:1.79%
controls:0.32%
cases:4.51%
controls:1.83%
12
60
504
5074
9
14
512
5166
—
5
0
516
5180
—
9
16
493
5001
20
81
423
4336
Supplier / Service Provider
OMOP5117446 [33004]
-6.7e-01
-3.8e-01
—
—
—
2.4e+00
2.8e+00
cases:15.70%
controls:26.70%
cases:5.76%
controls:8.20%
—
—
—
—
—
—
cases:6.37%
controls:0.60%
cases:14.22%
controls:1.02%
81
1371
435
3763
30
425
491
4755
—
—
—
32
30
470
4987
63
45
380
4372
Base excess in Venous blood by calculation
1927-3 [3002032]
5.3e-01
1.3e+00
—
—
2.0e+00
1.2e+00
7.5e-01
cases:2.71%
controls:1.62%
cases:3.45%
controls:0.98%
—
—
—
—
cases:1.16%
controls:0.15%
cases:2.99%
controls:0.90%
cases:4.74%
controls:2.29%
14
83
502
5051
18
51
503
5129
—
—
6
8
513
5168
15
45
487
4972
21
101
422
4316
Internal Medicine
11 [38004456]
5.0e-01
7.0e-01
1.3e+00
—
9.3e-01
6.5e-01
4.4e-01
cases:26.94%
controls:18.27%
cases:14.78%
controls:7.90%
cases:4.22%
controls:1.24%
—
—
cases:3.28%
controls:1.31%
cases:13.15%
controls:7.34%
cases:23.70%
controls:16.64%
139
938
377
4196
77
409
444
4771
22
64
499
5116
—
17
68
502
5108
66
368
436
4649
105
735
338
3682
Myopia
H52.1 [45533352]
—
—
—
1.0e+50
—
2.3e+00
2.2e+00
—
—
—
—
—
—
cases:2.11%
controls:0.00%
—
—
cases:1.39%
controls:0.14%
cases:2.48%
controls:0.29%
—
—
—
11
0
510
5180
—
7
7
495
5010
11
13
432
4404
Speech therapy
R4130 [2001310235]
2.3e+00
2.2e+00
—
—
—
1.7e+00
1.4e+00
cases:1.16%
controls:0.12%
cases:1.15%
controls:0.14%
—
—
—
—
—
—
cases:1.00%
controls:0.18%
cases:1.13%
controls:0.29%
6
6
510
5128
6
7
515
5173
—
—
—
5
9
497
5008
5
13
438
4404
timolol, combinations
S01ED51 [21603705]
1.1e+00
1.0e+00
1.3e+00
—
1.5e+00
1.2e+00
1.1e+00
cases:2.91%
controls:1.01%
cases:3.07%
controls:1.12%
cases:1.54%
controls:0.44%
—
—
cases:1.35%
controls:0.31%
cases:2.99%
controls:0.90%
cases:4.51%
controls:1.52%
15
52
501
5082
16
58
505
5122
8
23
513
5157
—
7
16
512
5160
15
45
487
4972
20
67
423
4350
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
1.4e+00
1.8e+00
—
—
—
1.6e+00
1.2e+00
cases:1.94%
controls:0.49%
cases:1.34%
controls:0.23%
—
—
—
—
—
—
cases:1.20%
controls:0.24%
cases:2.71%
controls:0.79%
10
25
506
5109
7
12
514
5168
—
—
—
6
12
496
5005
12
35
431
4382
Varicella zoster virus Ab [Titer] in Serum
21594-7 [3014148]
—
—
—
—
—
2.3e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.12%
cases:1.58%
controls:0.20%
—
—
—
—
—
6
6
496
5011
7
9
436
4408
Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay
29662-4 [3012220]
—
2.1e+00
—
—
—
2.3e+00
2.1e+00
—
—
cases:0.96%
controls:0.12%
—
—
—
—
—
—
cases:1.20%
controls:0.12%
cases:1.58%
controls:0.20%
—
5
6
516
5174
—
—
—
6
6
496
5011
7
9
436
4408
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
8.2e-01
1.2e+00
—
—
2.1e+00
1.1e+00
3.7e-01
cases:2.91%
controls:1.31%
cases:3.65%
controls:1.10%
—
—
—
—
cases:1.35%
controls:0.17%
cases:3.19%
controls:1.10%
cases:2.93%
controls:2.04%
15
67
501
5067
19
57
502
5123
—
—
7
9
512
5167
16
55
486
4962
13
90
430
4327
Perimetry
XCK00 [2001301380]
1.1e+00
1.9e+00
—
1.0e+50
1.0e+50
2.5e+00
1.3e+00
cases:1.94%
controls:0.66%
cases:1.73%
controls:0.27%
—
—
cases:4.03%
controls:0.00%
cases:0.96%
controls:0.00%
cases:1.20%
controls:0.10%
cases:2.03%
controls:0.59%
10
34
506
5100
9
14
512
5166
—
21
0
500
5180
5
0
514
5176
6
5
496
5012
9
26
434
4391
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
3.7e-01
6.4e-01
1.1e+00
—
1.2e+00
9.1e-01
4.8e-01
cases:17.64%
controls:12.93%
cases:12.28%
controls:6.85%
cases:2.50%
controls:0.87%
—
—
cases:3.66%
controls:1.08%
cases:14.34%
controls:6.34%
cases:26.41%
controls:18.20%
91
664
425
4470
64
355
457
4825
13
45
508
5135
—
19
56
500
5120
72
318
430
4699
117
804
326
3613
lactulose; oral
A06AD11 [21600571]
1.0e+00
1.3e+00
—
—
—
1.9e+00
1.4e+00
cases:3.29%
controls:1.23%
cases:2.11%
controls:0.60%
—
—
—
—
—
—
cases:2.99%
controls:0.48%
cases:4.97%
controls:1.25%
17
63
499
5071
11
31
510
5149
—
—
—
15
24
487
4993
22
55
421
4362
Limited function/disability NOS
A28 [2002000162]
5.8e-01
1.0e+00
1.6e+00
—
1.6e+00
1.6e+00
1.0e+00
cases:2.91%
controls:1.66%
cases:2.50%
controls:0.89%
cases:1.54%
controls:0.33%
—
—
cases:1.54%
controls:0.31%
cases:5.58%
controls:1.18%
cases:6.77%
controls:2.58%
15
85
501
5049
13
46
508
5134
8
17
513
5163
—
8
16
511
5160
28
59
474
4958
30
114
413
4303
Intermittent esotropy
H50.30 [2000502352]
—
—
—
—
—
2.3e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.12%
cases:1.58%
controls:0.25%
—
—
—
—
—
6
6
496
5011
7
11
436
4406
Asthma, unspecified
J45.9 [45562456]
6.4e-01
7.9e-01
2.1e+00
—
—
1.2e+00
8.4e-01
cases:5.04%
controls:2.73%
cases:2.88%
controls:1.33%
cases:1.34%
controls:0.17%
—
—
—
—
cases:3.78%
controls:1.20%
cases:7.22%
controls:3.24%
26
140
490
4994
15
69
506
5111
7
9
514
5171
—
—
19
60
483
4957
32
143
411
4274
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.9e-01
5.3e-01
1.5e+00
—
2.0e+00
4.8e-01
3.5e-01
cases:16.47%
controls:12.84%
cases:10.17%
controls:6.24%
cases:2.50%
controls:0.56%
—
—
cases:5.39%
controls:0.75%
cases:9.56%
controls:6.16%
cases:22.80%
controls:17.30%
85
659
431
4475
53
323
468
4857
13
29
508
5151
—
28
39
491
5137
48
309
454
4708
101
764
342
3653
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
2.4e-01
1.1e+00
—
—
1.9e+00
1.0e+00
3.9e-01
cases:6.20%
controls:4.93%
cases:7.10%
controls:2.51%
—
—
—
—
cases:2.12%
controls:0.31%
cases:4.98%
controls:1.89%
cases:8.13%
controls:5.64%
32
253
484
4881
37
130
484
5050
—
—
11
16
508
5160
25
95
477
4922
36
249
407
4168
ECG with 12 standard connections
XF400 [2001303368]
1.1e+00
1.7e+00
—
1.0e+50
—
1.4e+00
1.1e+00
cases:4.26%
controls:1.52%
cases:3.45%
controls:0.62%
—
—
cases:1.73%
controls:0.00%
—
—
cases:1.99%
controls:0.52%
cases:3.39%
controls:1.11%
22
78
494
5056
18
32
503
5148
—
9
0
512
5180
—
10
26
492
4991
15
49
428
4368
clopidogrel; oral
B01AC04 [21600989]
1.2e-01
3.7e-01
—
—
1.9e+00
1.1e+00
8.8e-01
cases:2.33%
controls:2.06%
cases:2.11%
controls:1.47%
—
—
—
—
cases:1.93%
controls:0.29%
cases:3.78%
controls:1.28%
cases:4.74%
controls:2.01%
12
106
504
5028
11
76
510
5104
—
—
10
15
509
5161
19
64
483
4953
21
89
422
4328
pantoprazole; oral, parenteral
A02BC02 [21600097]
3.8e-01
6.5e-01
1.1e+00
—
1.1e+00
5.3e-01
4.7e-01
cases:19.38%
controls:14.12%
cases:14.40%
controls:8.07%
cases:4.80%
controls:1.68%
—
—
cases:5.20%
controls:1.76%
cases:12.95%
controls:8.07%
cases:24.15%
controls:16.55%
100
725
416
4409
75
418
446
4762
25
87
496
5093
—
27
91
492
5085
65
405
437
4612
107
731
336
3686
Inpatient Visit
IP [9201]
2.3e-01
7.2e-01
1.3e+00
1.0e+50
1.6e+00
8.2e-01
6.0e-01
cases:6.78%
controls:5.47%
cases:5.37%
controls:2.68%
cases:1.34%
controls:0.37%
cases:2.11%
controls:0.00%
cases:1.73%
controls:0.37%
cases:5.38%
controls:2.43%
cases:10.38%
controls:5.98%
35
281
481
4853
28
139
493
5041
7
19
514
5161
11
0
510
5180
9
19
510
5157
27
122
475
4895
46
264
397
4153
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
3.2e-01
5.9e-01
8.5e-01
—
1.1e+00
7.0e-01
4.2e-01
cases:20.74%
controls:15.91%
cases:16.89%
controls:10.10%
cases:4.61%
controls:2.03%
—
—
cases:5.78%
controls:1.95%
cases:17.53%
controls:9.51%
cases:29.35%
controls:21.44%
107
817
409
4317
88
523
433
4657
24
105
497
5075
—
30
101
489
5075
88
477
414
4540
130
947
313
3470
quetiapine; oral
N05AH04 [21604544]
8.6e-01
9.0e-01
1.2e+00
—
1.0e+00
1.2e+00
7.6e-01
cases:7.17%
controls:3.17%
cases:5.18%
controls:2.18%
cases:2.11%
controls:0.68%
—
—
cases:1.73%
controls:0.64%
cases:6.57%
controls:2.13%
cases:7.90%
controls:3.85%
37
163
479
4971
27
113
494
5067
11
35
510
5145
—
9
33
510
5143
33
107
469
4910
35
170
408
4247
Rehabilitation Hospital
283X00000X [38004285]
1.9e+00
—
—
—
—
—
1.8e+00
cases:1.74%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:1.58%
controls:0.27%
9
14
507
5120
—
—
—
—
—
7
12
436
4405
Differential panel, method unspecified - Blood
69738-3 [42870588]
6.5e-01
6.0e-01
8.8e-01
—
1.3e+00
8.9e-01
7.4e-01
cases:11.43%
controls:6.33%
cases:7.49%
controls:4.27%
cases:2.11%
controls:0.89%
—
—
cases:3.28%
controls:0.91%
cases:9.36%
controls:4.07%
cases:16.93%
controls:8.83%
59
325
457
4809
39
221
482
4959
11
46
510
5134
—
17
47
502
5129
47
204
455
4813
75
390
368
4027
Dysphagia
R13 [45573013]
8.6e-01
—
—
—
—
2.1e+00
1.5e+00
cases:1.55%
controls:0.66%
—
—
—
—
—
—
—
—
cases:1.99%
controls:0.26%
cases:2.93%
controls:0.66%
8
34
508
5100
—
—
—
—
10
13
492
5004
13
29
430
4388
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
1.1e+00
1.0e+00
—
—
—
1.4e+00
1.1e+00
cases:4.84%
controls:1.62%
cases:1.73%
controls:0.62%
—
—
—
—
—
—
cases:2.99%
controls:0.78%
cases:6.09%
controls:2.17%
25
83
491
5051
9
32
512
5148
—
—
—
15
39
487
4978
27
96
416
4321
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
4.4e-01
1.1e+00
1.8e+00
—
1.8e+00
1.4e+00
1.0e+00
cases:4.65%
controls:3.06%
cases:3.84%
controls:1.25%
cases:0.96%
controls:0.15%
—
—
cases:1.16%
controls:0.19%
cases:3.98%
controls:1.00%
cases:7.22%
controls:2.76%
24
157
492
4977
20
65
501
5115
5
8
516
5172
—
6
10
513
5166
20
50
482
4967
32
122
411
4295
Functional capacity evaluation
443351003 [40481051]
7.6e-01
1.3e+00
2.0e+00
—
—
1.3e+00
9.2e-01
cases:3.88%
controls:1.85%
cases:2.69%
controls:0.71%
cases:0.96%
controls:0.14%
—
—
—
—
cases:2.59%
controls:0.74%
cases:5.42%
controls:2.24%
20
95
496
5039
14
37
507
5143
5
7
516
5173
—
—
13
37
489
4980
24
99
419
4318
Physiotherapist
Z3226 [2001311560]
9.1e-01
1.4e+00
—
—
2.3e+00
1.2e+00
1.2e+00
cases:5.81%
controls:2.43%
cases:2.30%
controls:0.58%
—
—
—
—
cases:0.96%
controls:0.10%
cases:2.39%
controls:0.76%
cases:5.19%
controls:1.58%
30
125
486
5009
12
30
509
5150
—
—
5
5
514
5171
12
38
490
4979
23
70
420
4347
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
2.2e-01
7.8e-01
4.5e-01
—
1.4e+00
7.9e-01
5.6e-01
cases:11.24%
controls:9.23%
cases:10.94%
controls:5.33%
cases:1.92%
controls:1.24%
—
—
cases:4.24%
controls:1.12%
cases:10.76%
controls:5.16%
cases:19.64%
controls:12.23%
58
474
458
4660
57
276
464
4904
10
64
511
5116
—
22
58
497
5118
54
259
448
4758
87
540
356
3877
betahistine; oral
N07CA01 [21604833]
8.0e-01
—
—
—
—
2.0e+00
1.4e+00
cases:1.16%
controls:0.53%
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.24%
cases:2.26%
controls:0.57%
6
27
510
5107
—
—
—
—
9
12
493
5005
10
25
433
4392
Sequelae of cerebral infarction
I69.3 [45533476]
5.1e-01
1.4e+00
2.0e+00
—
—
1.7e+00
1.7e+00
cases:1.36%
controls:0.82%
cases:1.73%
controls:0.42%
cases:0.96%
controls:0.14%
—
—
—
—
cases:2.39%
controls:0.44%
cases:4.74%
controls:0.91%
7
42
509
5092
9
22
512
5158
5
7
516
5173
—
—
12
22
490
4995
21
40
422
4377
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
6.7e-01
7.4e-01
1.6e+00
—
2.0e+00
6.6e-01
4.3e-01
cases:10.27%
controls:5.51%
cases:6.33%
controls:3.13%
cases:1.54%
controls:0.33%
—
—
cases:1.93%
controls:0.27%
cases:4.98%
controls:2.63%
cases:12.19%
controls:8.31%
53
283
463
4851
33
162
488
5018
8
17
513
5163
—
10
14
509
5162
25
132
477
4885
54
367
389
4050
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.8e-01
7.0e-01
9.6e-01
—
1.2e+00
9.2e-01
5.9e-01
cases:13.57%
controls:9.72%
cases:11.32%
controls:5.98%
cases:2.88%
controls:1.12%
—
—
cases:3.85%
controls:1.22%
cases:12.55%
controls:5.40%
cases:21.44%
controls:13.11%
70
499
446
4635
59
310
462
4870
15
58
506
5122
—
20
63
499
5113
63
271
439
4746
95
579
348
3838
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
4.2e-01
5.4e-01
5.7e-01
—
1.5e+00
4.2e-01
4.6e-01
cases:30.23%
controls:22.15%
cases:20.15%
controls:12.84%
cases:3.26%
controls:1.87%
—
—
cases:6.36%
controls:1.43%
cases:18.73%
controls:13.16%
cases:43.57%
controls:32.67%
156
1137
360
3997
105
665
416
4515
17
97
504
5083
—
33
74
486
5102
94
660
408
4357
193
1443
250
2974
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
3.8e-01
7.1e-01
9.3e-01
—
1.2e+00
8.9e-01
5.9e-01
cases:13.57%
controls:9.70%
cases:11.32%
controls:5.93%
cases:2.88%
controls:1.16%
—
—
cases:3.85%
controls:1.20%
cases:12.35%
controls:5.46%
cases:20.99%
controls:12.86%
70
498
446
4636
59
307
462
4873
15
60
506
5120
—
20
62
499
5114
62
274
440
4743
93
568
350
3849
Monocytes [#/volume] in Blood
26484-6 [3001604]
3.7e-01
6.6e-01
7.6e-01
—
1.2e+00
8.9e-01
5.8e-01
cases:13.95%
controls:10.05%
cases:11.52%
controls:6.33%
cases:2.69%
controls:1.27%
—
—
cases:4.05%
controls:1.20%
cases:13.15%
controls:5.84%
cases:23.02%
controls:14.29%
72
516
444
4618
60
328
461
4852
14
66
507
5114
—
21
62
498
5114
66
293
436
4724
102
631
341
3786
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
3.1e-01
6.8e-01
9.3e-01
—
1.2e+00
9.0e-01
6.2e-01
cases:13.18%
controls:9.97%
cases:11.32%
controls:6.10%
cases:2.88%
controls:1.16%
—
—
cases:3.85%
controls:1.22%
cases:12.75%
controls:5.60%
cases:22.57%
controls:13.56%
68
512
448
4622
59
316
462
4864
15
60
506
5120
—
20
63
499
5113
64
281
438
4736
100
599
343
3818
Other investigative procedure of eye
XCW99 [2001301491]
5.9e-01
1.3e+00
—
1.0e+50
—
1.8e+00
1.5e+00
cases:2.13%
controls:1.19%
cases:1.73%
controls:0.48%
—
—
cases:4.22%
controls:0.00%
—
—
cases:2.19%
controls:0.36%
cases:5.64%
controls:1.27%
11
61
505
5073
9
25
512
5155
—
22
0
499
5180
—
11
18
491
4999
25
56
418
4361
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.7e-01
6.6e-01
8.9e-01
—
1.2e+00
9.3e-01
6.0e-01
cases:13.37%
controls:9.66%
cases:10.94%
controls:5.97%
cases:2.69%
controls:1.12%
—
—
cases:3.85%
controls:1.22%
cases:12.55%
controls:5.38%
cases:21.44%
controls:13.09%
69
496
447
4638
57
309
464
4871
14
58
507
5122
—
20
63
499
5113
63
270
439
4747
95
578
348
3839
azathioprine; oral, parenteral
L04AX01 [21603927]
9.2e-01
1.7e+00
—
—
—
1.7e+00
1.7e+00
cases:1.16%
controls:0.47%
cases:1.34%
controls:0.25%
—
—
—
—
—
—
cases:1.59%
controls:0.30%
cases:2.71%
controls:0.52%
6
24
510
5110
7
13
514
5167
—
—
—
8
15
494
5002
12
23
431
4394
Osmolality of Urine
2695-5 [3026782]
5.6e-01
1.2e+00
—
—
1.5e+00
1.2e+00
9.9e-01
cases:7.17%
controls:4.21%
cases:4.99%
controls:1.58%
—
—
—
—
cases:0.96%
controls:0.21%
cases:3.98%
controls:1.26%
cases:8.13%
controls:3.19%
37
216
479
4918
26
82
495
5098
—
—
5
11
514
5165
20
63
482
4954
36
141
407
4276
Basophils [#/volume] in Blood
26444-0 [3006315]
3.3e-01
6.3e-01
7.6e-01
—
1.2e+00
8.9e-01
5.7e-01
cases:13.57%
controls:10.11%
cases:11.32%
controls:6.35%
cases:2.69%
controls:1.27%
—
—
cases:4.05%
controls:1.20%
cases:13.15%
controls:5.84%
cases:23.02%
controls:14.42%
70
519
446
4615
59
329
462
4851
14
66
507
5114
—
21
62
498
5114
66
293
436
4724
102
637
341
3780
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
3.3e-01
6.3e-01
7.3e-01
—
1.2e+00
8.5e-01
6.0e-01
cases:13.95%
controls:10.42%
cases:11.32%
controls:6.39%
cases:2.69%
controls:1.31%
—
—
cases:4.05%
controls:1.20%
cases:12.95%
controls:6.00%
cases:24.15%
controls:14.83%
72
535
444
4599
59
331
462
4849
14
68
507
5112
—
21
62
498
5114
65
301
437
4716
107
655
336
3762
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.6e-01
6.6e-01
9.6e-01
—
1.1e+00
9.1e-01
6.0e-01
cases:13.37%
controls:9.68%
cases:10.94%
controls:5.97%
cases:2.88%
controls:1.12%
—
—
cases:3.66%
controls:1.22%
cases:12.55%
controls:5.44%
cases:21.44%
controls:13.04%
69
497
447
4637
57
309
464
4871
15
58
506
5122
—
19
63
500
5113
63
273
439
4744
95
576
348
3841
Moderate visual impairment, binocular
H54.2 [45567102]
—
—
—
1.0e+50
—
—
3.3e+00
—
—
—
—
—
—
cases:1.34%
controls:0.00%
—
—
—
—
cases:2.93%
controls:0.11%
—
—
—
7
0
514
5180
—
—
13
5
430
4412
Eosinophils [#/volume] in Blood
26449-9 [3013115]
3.4e-01
6.5e-01
8.0e-01
—
1.2e+00
8.7e-01
5.4e-01
cases:14.34%
controls:10.63%
cases:11.71%
controls:6.49%
cases:3.07%
controls:1.41%
—
—
cases:4.24%
controls:1.29%
cases:13.35%
controls:6.04%
cases:23.02%
controls:14.87%
74
546
442
4588
61
336
460
4844
16
73
505
5107
—
22
67
497
5109
67
303
435
4714
102
657
341
3760
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.2e-01
7.2e-01
8.3e-01
—
1.1e+00
8.9e-01
5.4e-01
cases:18.02%
controls:13.81%
cases:13.82%
controls:7.22%
cases:2.50%
controls:1.10%
—
—
cases:3.47%
controls:1.16%
cases:15.54%
controls:7.00%
cases:27.99%
controls:18.50%
93
709
423
4425
72
374
449
4806
13
57
508
5123
—
18
60
501
5116
78
351
424
4666
124
817
319
3600
Hypothyroidism, unspecified
E03.9 [45537945]
6.2e-01
1.2e+00
—
—
—
1.1e+00
9.4e-01
cases:3.29%
controls:1.79%
cases:2.30%
controls:0.69%
—
—
—
—
—
—
cases:2.59%
controls:0.88%
cases:5.64%
controls:2.29%
17
92
499
5042
12
36
509
5144
—
—
—
13
44
489
4973
25
101
418
4316
escitalopram; oral
N06AB10 [21604718]
7.1e-01
4.5e-01
1.3e+00
—
—
1.3e+00
1.2e+00
cases:6.20%
controls:3.14%
cases:2.88%
controls:1.85%
cases:1.54%
controls:0.44%
—
—
—
—
cases:6.18%
controls:1.75%
cases:10.61%
controls:3.51%
32
161
484
4973
15
96
506
5084
8
23
513
5157
—
—
31
88
471
4929
47
155
396
4262
pH of Serum or Plasma
2753-2 [3018418]
8.1e-01
7.8e-01
—
—
1.3e+00
9.4e-01
6.6e-01
cases:10.08%
controls:4.73%
cases:5.76%
controls:2.72%
—
—
—
—
cases:1.73%
controls:0.48%
cases:6.57%
controls:2.67%
cases:11.96%
controls:6.54%
52
243
464
4891
30
141
491
5039
—
—
9
25
510
5151
33
134
469
4883
53
289
390
4128
Bacteria identified in Urine by Culture
630-4 [3026008]
4.6e-01
5.7e-01
—
—
1.6e+00
7.9e-01
7.6e-01
cases:6.78%
controls:4.40%
cases:4.22%
controls:2.43%
—
—
—
—
cases:1.73%
controls:0.35%
cases:4.98%
controls:2.31%
cases:13.77%
controls:6.97%
35
226
481
4908
22
126
499
5054
—
—
9
18
510
5158
25
116
477
4901
61
308
382
4109
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
8.0e-01
1.1e+00
—
—
—
1.9e+00
1.2e+00
cases:2.13%
controls:0.97%
cases:1.34%
controls:0.44%
—
—
—
—
—
—
cases:2.19%
controls:0.34%
cases:4.29%
controls:1.27%
11
50
505
5084
7
23
514
5157
—
—
—
11
17
491
5000
19
56
424
4361
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
9.2e-01
3.8e-01
—
—
—
1.3e+00
8.4e-01
cases:3.88%
controls:1.58%
cases:0.96%
controls:0.66%
—
—
—
—
—
—
cases:2.39%
controls:0.64%
cases:4.74%
controls:2.11%
20
81
496
5053
5
34
516
5146
—
—
—
12
32
490
4985
21
93
422
4324
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
7.7e-01
1.4e+00
—
1.0e+50
—
1.7e+00
1.4e+00
cases:3.10%
controls:1.46%
cases:1.34%
controls:0.33%
—
—
cases:1.34%
controls:0.00%
—
—
cases:2.39%
controls:0.44%
cases:4.74%
controls:1.27%
16
75
500
5059
7
17
514
5163
—
7
0
514
5180
—
12
22
490
4995
21
56
422
4361
Intravenous
ZX120 [2001311495]
7.7e-01
5.4e-01
—
—
—
1.6e+00
1.4e+00
cases:2.33%
controls:1.09%
cases:0.96%
controls:0.56%
—
—
—
—
—
—
cases:1.59%
controls:0.32%
cases:3.16%
controls:0.77%
12
56
504
5078
5
29
516
5151
—
—
—
8
16
494
5001
14
34
429
4383
Concussion
S06.0 [45582805]
1.1e+00
1.8e+00
—
—
—
9.7e-01
6.5e-01
cases:2.91%
controls:0.97%
cases:2.50%
controls:0.41%
—
—
—
—
—
—
cases:1.00%
controls:0.38%
cases:2.48%
controls:1.31%
15
50
501
5084
13
21
508
5159
—
—
—
5
19
497
4998
11
58
432
4359
prednisolone
A07EA01 [21600653]
3.6e-01
7.6e-01
1.3e+00
—
1.3e+00
8.1e-01
3.8e-01
cases:12.60%
controls:9.10%
cases:8.45%
controls:4.13%
cases:2.11%
controls:0.60%
—
—
cases:2.70%
controls:0.71%
cases:8.17%
controls:3.81%
cases:14.00%
controls:9.98%
65
467
451
4667
44
214
477
4966
11
31
510
5149
—
14
37
505
5139
41
191
461
4826
62
441
381
3976
prednisolone; oral, parenteral
H02AB06 [21602734]
3.7e-01
7.4e-01
1.3e+00
—
1.3e+00
8.2e-01
3.9e-01
cases:12.60%
controls:9.06%
cases:8.25%
controls:4.11%
cases:2.11%
controls:0.60%
—
—
cases:2.70%
controls:0.71%
cases:8.17%
controls:3.79%
cases:14.00%
controls:9.94%
65
465
451
4669
43
213
478
4967
11
31
510
5149
—
14
37
505
5139
41
190
461
4827
62
439
381
3978
Supine thorax X-ray examination
GD1QA [2001303648]
9.0e-01
2.0e+00
—
—
—
8.3e-01
8.9e-01
cases:3.10%
controls:1.29%
cases:3.07%
controls:0.44%
—
—
—
—
—
—
cases:1.00%
controls:0.44%
cases:5.64%
controls:2.40%
16
66
500
5068
16
23
505
5157
—
—
—
5
22
497
4995
25
106
418
4311
EKG study
11524-6 [3013512]
3.7e-01
6.8e-01
9.5e-01
—
1.6e+00
3.6e-01
5.7e-01
cases:8.33%
controls:5.88%
cases:5.95%
controls:3.11%
cases:1.54%
controls:0.60%
—
—
cases:2.12%
controls:0.44%
cases:4.98%
controls:3.53%
cases:12.64%
controls:7.54%
43
302
473
4832
31
161
490
5019
8
31
513
5149
—
11
23
508
5153
25
177
477
4840
56
333
387
4084
Glaucoma secondary to other eye disorders
H40.5 [45571978]
—
—
—
1.0e+50
—
—
2.8e+00
—
—
—
—
—
—
cases:1.34%
controls:0.00%
—
—
—
—
cases:2.26%
controls:0.14%
—
—
—
7
0
514
5180
—
—
10
6
433
4411
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
2.5e-01
5.3e-01
6.2e-01
—
9.8e-01
7.6e-01
5.6e-01
cases:14.73%
controls:11.86%
cases:12.28%
controls:7.61%
cases:3.84%
controls:2.10%
—
—
cases:5.01%
controls:1.93%
cases:13.94%
controls:7.08%
cases:24.38%
controls:15.58%
76
609
440
4525
64
394
457
4786
20
109
501
5071
—
26
100
493
5076
70
355
432
4662
108
688
335
3729
Pain in limb
M79.6 [45587063]
2.4e-01
5.6e-01
2.0e+00
—
—
8.7e-01
3.2e-01
cases:6.98%
controls:5.59%
cases:3.84%
controls:2.24%
cases:1.34%
controls:0.19%
—
—
—
—
cases:4.58%
controls:1.97%
cases:10.61%
controls:7.90%
36
287
480
4847
20
116
501
5064
7
10
514
5170
—
—
23
99
479
4918
47
349
396
4068
Extensive MRI examination of brain with 3 Tesla magnet
AA1CM [2001300117]
2.8e+00
—
—
—
—
1.0e+50
—
cases:1.55%
controls:0.10%
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.00%
—
—
8
5
508
5129
—
—
—
—
5
0
497
5017
—
amantadine; oral
N04BB01 [21604471]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.16%
—
—
—
—
—
—
11
7
432
4410
No procedures
SPAT1301 [2001700402]
4.0e-01
6.8e-01
—
—
1.9e+00
8.5e-01
5.9e-01
cases:7.75%
controls:5.36%
cases:3.65%
controls:1.87%
—
—
—
—
cases:1.54%
controls:0.23%
cases:3.98%
controls:1.73%
cases:9.26%
controls:5.37%
40
275
476
4859
19
97
502
5083
—
—
8
12
511
5164
20
87
482
4930
41
237
402
4180
Bacteria identified in Blood by Culture
600-7 [3023368]
2.1e-01
7.4e-01
—
—
1.7e+00
1.1e+00
6.2e-01
cases:5.04%
controls:4.13%
cases:4.22%
controls:2.07%
—
—
—
—
cases:1.54%
controls:0.29%
cases:5.38%
controls:1.93%
cases:8.35%
controls:4.66%
26
212
490
4922
22
107
499
5073
—
—
8
15
511
5161
27
97
475
4920
37
206
406
4211
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
7.3e-01
1.1e+00
—
—
—
1.1e+00
9.3e-01
cases:6.40%
controls:3.17%
cases:2.50%
controls:0.87%
—
—
—
—
—
—
cases:1.99%
controls:0.68%
cases:6.09%
controls:2.49%
33
163
483
4971
13
45
508
5135
—
—
—
10
34
492
4983
27
110
416
4307
Other visual field testing
CS494 [2001301478]
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.12%
—
—
—
—
—
—
—
9
6
493
5011
—
Essential (primary) hypertension
I10 [45591453]
4.0e-01
6.3e-01
9.1e-01
—
9.5e-01
6.1e-01
4.9e-01
cases:17.83%
controls:12.70%
cases:10.94%
controls:6.16%
cases:2.88%
controls:1.18%
—
—
cases:3.28%
controls:1.29%
cases:11.75%
controls:6.76%
cases:23.02%
controls:15.44%
92
652
424
4482
57
319
464
4861
15
61
506
5119
—
17
67
502
5109
59
339
443
4678
102
682
341
3735
hypromellose
S01KA02 [21605115]
7.8e-01
8.3e-01
—
—
—
1.7e+00
1.0e+00
cases:3.29%
controls:1.54%
cases:1.54%
controls:0.68%
—
—
—
—
—
—
cases:3.19%
controls:0.62%
cases:4.74%
controls:1.79%
17
79
499
5055
8
35
513
5145
—
—
—
16
31
486
4986
21
79
422
4338
Polyneuropathy, unspecified
G62.9 [45566898]
1.6e+00
—
—
—
—
2.7e+00
1.5e+00
cases:1.16%
controls:0.23%
—
—
—
—
—
—
—
—
cases:1.39%
controls:0.10%
cases:1.58%
controls:0.34%
6
12
510
5122
—
—
—
—
7
5
495
5012
7
15
436
4402
Multiple sclerosis
109 [2001600109]
2.6e+00
—
—
—
—
1.0e+50
—
cases:1.36%
controls:0.10%
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.00%
—
—
7
5
509
5129
—
—
—
—
9
0
493
5017
—
Subjective visual disturbances
H53.1 [45557467]
1.1e+00
2.6e+00
—
1.0e+50
—
—
1.5e+00
cases:1.74%
controls:0.58%
cases:2.11%
controls:0.15%
—
—
cases:1.54%
controls:0.00%
—
—
—
—
cases:1.58%
controls:0.34%
9
30
507
5104
11
8
510
5172
—
8
0
513
5180
—
—
7
15
436
4402
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
9.3e-01
7.8e-01
—
—
—
1.5e+00
1.1e+00
cases:2.52%
controls:1.01%
cases:1.34%
controls:0.62%
—
—
—
—
—
—
cases:1.79%
controls:0.40%
cases:3.16%
controls:1.09%
13
52
503
5082
7
32
514
5148
—
—
—
9
20
493
4997
14
48
429
4369
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 [3016543]
1.1e+00
2.6e+00
—
—
1.0e+50
—
1.1e+00
cases:1.16%
controls:0.39%
cases:1.54%
controls:0.12%
—
—
—
—
cases:0.96%
controls:0.00%
—
—
cases:1.13%
controls:0.38%
6
20
510
5114
8
6
513
5174
—
—
5
0
514
5176
—
5
17
438
4400
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
1.1e+00
2.6e+00
—
—
1.0e+50
—
1.1e+00
cases:1.16%
controls:0.39%
cases:1.54%
controls:0.12%
—
—
—
—
cases:0.96%
controls:0.00%
—
—
cases:1.13%
controls:0.38%
6
20
510
5114
8
6
513
5174
—
—
5
0
514
5176
—
5
17
438
4400
Medical doctor
Z2221 [2001311556]
6.7e-01
6.9e-01
—
—
—
9.8e-01
9.0e-01
cases:8.14%
controls:4.32%
cases:3.07%
controls:1.56%
—
—
—
—
—
—
cases:3.19%
controls:1.22%
cases:7.67%
controls:3.26%
42
222
474
4912
16
81
505
5099
—
—
—
16
61
486
4956
34
144
409
4273
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
4.2e-01
9.3e-01
—
—
1.4e+00
9.7e-01
6.5e-01
cases:9.69%
controls:6.60%
cases:8.25%
controls:3.42%
—
—
—
—
cases:1.93%
controls:0.50%
cases:7.97%
controls:3.19%
cases:14.45%
controls:8.08%
50
339
466
4795
43
177
478
5003
—
—
10
26
509
5150
40
160
462
4857
64
357
379
4060
Weakness/tiredness general
A04 [2002000145]
3.7e-01
1.2e+00
—
—
—
1.7e+00
8.7e-01
cases:1.94%
controls:1.34%
cases:1.92%
controls:0.58%
—
—
—
—
—
—
cases:2.39%
controls:0.46%
cases:5.42%
controls:2.35%
10
69
506
5065
10
30
511
5150
—
—
—
12
23
490
4994
24
104
419
4313
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
6.3e-01
1.2e+00
—
—
1.5e+00
1.4e+00
5.1e-01
cases:4.65%
controls:2.53%
cases:4.99%
controls:1.60%
—
—
—
—
cases:1.35%
controls:0.31%
cases:4.18%
controls:1.12%
cases:5.64%
controls:3.46%
24
130
492
5004
26
83
495
5097
—
—
7
16
512
5160
21
56
481
4961
25
153
418
4264
More than one and less than three hours
ZXE10 [2001311401]
7.1e-01
9.4e-01
-1.0e+50
—
—
5.6e-01
8.6e-01
cases:10.27%
controls:5.34%
cases:4.03%
controls:1.62%
cases:0.00%
controls:0.17%
—
—
—
—
cases:2.39%
controls:1.38%
cases:7.00%
controls:3.08%
53
274
463
4860
21
84
500
5096
0
9
521
5171
—
—
12
69
490
4948
31
136
412
4281
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
3.6e-01
5.0e-01
5.0e-01
—
1.5e+00
3.3e-01
4.8e-01
cases:22.48%
controls:16.87%
cases:13.82%
controls:8.90%
cases:2.30%
controls:1.41%
—
—
cases:4.43%
controls:1.00%
cases:12.75%
controls:9.47%
cases:34.54%
controls:24.63%
116
866
400
4268
72
461
449
4719
12
73
509
5107
—
23
52
496
5124
64
475
438
4542
153
1088
290
3329
acetazolamide; oral, parenteral
S01EC01 [21603693]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.11%
—
—
—
—
—
—
6
5
437
4412
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
157 [2001600155]
2.5e+00
—
—
—
—
1.0e+50
—
cases:1.16%
controls:0.10%
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.00%
—
—
6
5
510
5129
—
—
—
—
6
0
496
5017
—
Gas panel - Venous blood
24339-4 [3000991]
6.7e-01
1.2e+00
—
—
—
1.2e+00
5.6e-01
cases:2.71%
controls:1.40%
cases:3.07%
controls:0.91%
—
—
—
—
—
—
cases:2.59%
controls:0.78%
cases:3.39%
controls:1.97%
14
72
502
5062
16
47
505
5133
—
—
—
13
39
489
4978
15
87
428
4330
Extensive abdominal CT
JN3BD [2001305556]
5.1e-01
2.5e+00
—
—
—
—
1.1e+00
cases:1.36%
controls:0.82%
cases:1.34%
controls:0.12%
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.45%
7
42
509
5092
7
6
514
5174
—
—
—
—
6
20
437
4397
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
5.2e-01
1.0e+00
—
—
1.3e+00
8.4e-01
5.8e-01
cases:8.14%
controls:5.01%
cases:7.29%
controls:2.74%
—
—
—
—
cases:1.54%
controls:0.44%
cases:5.98%
controls:2.67%
cases:10.84%
controls:6.36%
42
257
474
4877
38
142
483
5038
—
—
8
23
511
5153
30
134
472
4883
48
281
395
4136
Glucose [Moles/volume] in Cerebral spinal fluid
14744-7 [3020044]
8.2e-01
2.4e+00
—
—
1.0e+50
—
9.7e-01
cases:0.97%
controls:0.43%
cases:1.54%
controls:0.14%
—
—
—
—
cases:1.16%
controls:0.00%
—
—
cases:1.13%
controls:0.43%
5
22
511
5112
8
7
513
5173
—
—
6
0
513
5176
—
5
19
438
4398
Pharmacy visit
OMOP4822462 [581458]
3.5e-01
5.4e-01
7.3e-01
7.4e-01
6.3e-01
5.4e-01
7.1e-01
cases:93.99%
controls:91.68%
cases:87.52%
controls:80.42%
cases:57.97%
controls:39.94%
cases:4.41%
controls:2.16%
cases:56.65%
controls:40.96%
cases:87.85%
controls:80.87%
cases:97.29%
controls:94.66%
485
4707
31
427
456
4166
65
1014
302
2069
219
3111
23
112
498
5068
294
2120
225
3056
441
4057
61
960
431
4181
12
236
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
303 [2001600260]
2.4e+00
—
—
—
—
—
—
cases:1.74%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
9
8
507
5126
—
—
—
—
—
—
Sleep apnoea
G47.3 [45562094]
4.1e-01
7.3e-01
9.8e-01
—
5.6e-01
8.0e-01
8.4e-01
cases:5.62%
controls:3.82%
cases:5.18%
controls:2.57%
cases:1.54%
controls:0.58%
—
—
cases:1.35%
controls:0.77%
cases:5.18%
controls:2.39%
cases:9.26%
controls:4.21%
29
196
487
4938
27
133
494
5047
8
30
513
5150
—
7
40
512
5136
26
120
476
4897
41
186
402
4231
Plain photography of ocular fundus
CK2S4 [2001301455]
9.2e-01
1.4e+00
—
1.0e+50
—
2.3e+00
—
cases:1.74%
controls:0.70%
cases:0.96%
controls:0.23%
—
—
cases:1.34%
controls:0.00%
—
—
cases:2.19%
controls:0.22%
—
—
9
36
507
5098
5
12
516
5168
—
7
0
514
5180
—
11
11
491
5006
—
brimonidine
S01GA07 [947915]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.58%
controls:0.16%
—
—
—
—
—
—
7
7
436
4410
brimonidine
S01EA05 [21603677]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.58%
controls:0.16%
—
—
—
—
—
—
7
7
436
4410
Voluntary or Charitable Agency
251V00000X [38004202]
—
—
—
—
—
2.3e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.12%
cases:1.81%
controls:0.61%
—
—
—
—
—
6
6
496
5011
8
27
435
4390
Other chronic pain
R52.2 [45568139]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.12%
—
—
—
—
—
—
—
6
6
496
5011
—
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
182 [2001600181]
2.3e+00
—
—
—
—
—
—
cases:1.36%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
509
5127
—
—
—
—
—
—
Intermittent exotropia
H50.31 [2000502353]
2.3e+00
—
—
1.0e+50
—
—
—
cases:1.16%
controls:0.12%
—
—
—
—
cases:0.96%
controls:0.00%
—
—
—
—
—
—
6
6
510
5128
—
—
5
0
516
5180
—
—
—
Cathetrisation of vein
TPH04 [2001309597]
8.6e-01
1.4e+00
—
—
—
1.0e+00
7.3e-01
cases:5.04%
controls:2.20%
cases:3.45%
controls:0.85%
—
—
—
—
—
—
cases:2.19%
controls:0.82%
cases:4.97%
controls:2.47%
26
113
490
5021
18
44
503
5136
—
—
—
11
41
491
4976
22
109
421
4308
Normoblasts [#/volume] in Blood
715-3 [3021589]
2.9e-01
5.2e-01
6.8e-01
—
1.1e+00
6.0e-01
4.3e-01
cases:11.24%
controls:8.65%
cases:11.13%
controls:6.95%
cases:3.07%
controls:1.58%
—
—
cases:4.24%
controls:1.39%
cases:11.35%
controls:6.54%
cases:18.51%
controls:12.84%
58
444
458
4690
58
360
463
4820
16
82
505
5098
—
22
72
497
5104
57
328
445
4689
82
567
361
3850
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
3.8e-01
4.7e-01
7.8e-01
—
1.6e+00
5.9e-01
3.1e-01
cases:21.12%
controls:15.52%
cases:11.90%
controls:7.78%
cases:2.69%
controls:1.25%
—
—
cases:5.59%
controls:1.14%
cases:12.55%
controls:7.35%
cases:26.64%
controls:21.08%
109
797
407
4337
62
403
459
4777
14
65
507
5115
—
29
59
490
5117
63
369
439
4648
118
931
325
3486
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
5.1e-02
8.9e-01
1.1e+00
—
1.7e+00
1.3e+00
6.0e-01
cases:3.68%
controls:3.51%
cases:4.41%
controls:1.85%
cases:0.96%
controls:0.33%
—
—
cases:0.96%
controls:0.17%
cases:4.38%
controls:1.20%
cases:6.55%
controls:3.69%
19
180
497
4954
23
96
498
5084
5
17
516
5163
—
5
9
514
5167
22
60
480
4957
29
163
414
4254
Epilepsy and comparable convulsive disorders
111 [2001600111]
2.2e+00
—
—
—
—
—
—
cases:1.94%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
10
11
506
5123
—
—
—
—
—
—
Epilepsy
G40 [45595935]
2.2e+00
—
—
—
—
—
1.5e+00
cases:1.74%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:1.13%
controls:0.25%
9
10
507
5124
—
—
—
—
—
5
11
438
4406
Very extensive MRI examination of brain with high intensity magnet
AA1DG [2001300120]
2.2e+00
—
—
—
—
2.3e+00
2.1e+00
cases:1.74%
controls:0.19%
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.10%
cases:1.13%
controls:0.14%
9
10
507
5124
—
—
—
—
5
5
497
5012
5
6
438
4411
Geriatric Psychiatry
27 [38004470]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.81%
controls:0.20%
—
—
—
—
—
—
8
9
435
4408
Immunofixation for Serum or Plasma
25700-6 [3037756]
—
-1.0e+50
—
—
—
—
2.2e+00
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
cases:1.81%
controls:0.20%
—
0
7
521
5173
—
—
—
—
8
9
435
4408
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
4.3e-01
9.1e-01
—
—
1.3e+00
7.5e-01
5.3e-01
cases:8.72%
controls:5.86%
cases:7.49%
controls:3.17%
—
—
—
—
cases:1.73%
controls:0.48%
cases:6.37%
controls:3.11%
cases:11.96%
controls:7.38%
45
301
471
4833
39
164
482
5016
—
—
9
25
510
5151
32
156
470
4861
53
326
390
4091
Hypermetropia
H52.0 [45543078]
—
-1.0e+50
—
—
—
2.2e+00
9.7e-01
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
cases:1.39%
controls:0.16%
cases:1.13%
controls:0.43%
—
0
9
521
5171
—
—
—
7
8
495
5009
5
19
438
4398
Abdominal X-ray examination without contrast
JN3AA [2001305553]
2.2e+00
—
—
—
—
—
—
cases:1.36%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
7
8
509
5126
—
—
—
—
—
—
Malaise and fatigue
R53 [45553741]
1.2e-01
1.5e+00
—
—
—
4.5e-01
7.1e-01
cases:2.71%
controls:2.42%
cases:3.45%
controls:0.83%
—
—
—
—
—
—
cases:1.79%
controls:1.16%
cases:7.22%
controls:3.69%
14
124
502
5010
18
43
503
5137
—
—
—
9
58
493
4959
32
163
411
4254
Benign neoplasm: Transverse colon
D12.3 [45581282]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.16%
—
—
—
—
—
—
6
7
437
4410
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
3.3e-01
4.3e-01
—
—
1.5e+00
6.0e-01
6.4e-01
cases:9.30%
controls:6.84%
cases:6.14%
controls:4.07%
—
—
—
—
cases:1.73%
controls:0.39%
cases:6.97%
controls:3.97%
cases:20.32%
controls:11.86%
48
351
468
4783
32
211
489
4969
—
—
9
20
510
5156
35
199
467
4818
90
524
353
3893
Cerebral infarction due to thrombosis of cerebral arteries
I63.3 [45562366]
—
2.3e+00
—
—
—
—
2.1e+00
—
—
cases:0.96%
controls:0.10%
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.25%
—
5
5
516
5175
—
—
—
—
9
11
434
4406
Noninfective gastroenteritis and colitis, unspecified
K52.9 [45572215]
2.1e+00
—
—
—
—
-1.0e+50
—
cases:1.36%
controls:0.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
7
9
509
5125
—
—
—
—
0
6
502
5011
—
Lumbar spine X-ray examination with flexion
NA3EA [2001307044]
2.1e+00
—
—
—
—
—
—
cases:1.36%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
509
5125
—
—
—
—
—
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
5.1e-01
8.9e-01
—
—
1.1e+00
6.6e-01
4.9e-01
cases:9.88%
controls:6.16%
cases:8.45%
controls:3.65%
—
—
—
—
cases:1.73%
controls:0.58%
cases:6.97%
controls:3.73%
cases:14.22%
controls:9.24%
51
316
465
4818
44
189
477
4991
—
—
9
30
510
5146
35
187
467
4830
63
408
380
4009
Hypokalaemia
E87.6 [45537991]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.27%
—
—
—
—
—
—
9
12
434
4405
Rectal ultrasound examination of prostate
KE1BE [2001306106]
6.7e-01
-1.0e+50
—
—
—
2.0e+00
—
cases:1.36%
controls:0.70%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:1.20%
controls:0.16%
—
—
7
36
509
5098
0
19
521
5161
—
—
—
6
8
496
5009
—
Conjunctival surface anesthesia
WX100 [2001310764]
2.9e-01
-1.0e+50
—
—
—
2.0e+00
7.8e-01
cases:1.16%
controls:0.88%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:1.20%
controls:0.16%
cases:2.48%
controls:1.15%
6
45
510
5089
0
11
521
5169
—
—
—
6
8
496
5009
11
51
432
4366
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood
88518-6 [36304997]
9.7e-01
-1.0e+50
—
—
—
2.0e+00
1.1e+00
cases:0.97%
controls:0.37%
cases:0.00%
controls:0.17%
—
—
—
—
—
—
cases:1.20%
controls:0.16%
cases:1.81%
controls:0.63%
5
19
511
5115
0
9
521
5171
—
—
—
6
8
496
5009
8
28
435
4389
sucralfate; oral
A02BX02 [21600111]
2.0e+00
—
—
—
—
—
—
cases:1.16%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
510
5126
—
—
—
—
—
—
Counselling and guidance related to physical exercise
SPAT1305 [2001700406]
6.4e-01
2.0e+00
—
—
—
—
1.0e+00
cases:1.36%
controls:0.72%
cases:1.15%
controls:0.15%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.88%
7
37
509
5097
6
8
515
5172
—
—
—
—
11
39
432
4378
Application of soft bandage
SPAT1211 [2001700312]
6.6e-01
—
—
—
—
2.0e+00
—
cases:1.94%
controls:1.01%
—
—
—
—
—
—
—
—
cases:1.59%
controls:0.22%
—
—
10
52
506
5082
—
—
—
—
8
11
494
5006
—
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
—
—
—
—
—
2.0e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:1.59%
controls:0.22%
cases:1.81%
controls:0.43%
—
—
—
—
—
8
11
494
5006
8
19
435
4398
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
1.6e-01
8.4e-01
—
—
—
1.2e+00
4.3e-01
cases:6.20%
controls:5.34%
cases:5.76%
controls:2.57%
—
—
—
—
—
—
cases:5.18%
controls:1.69%
cases:7.67%
controls:5.12%
32
274
484
4860
30
133
491
5047
—
—
—
26
85
476
4932
34
226
409
4191
One-surface restoration
SFA10 [2001310358]
1.4e-01
5.2e-01
1.5e+00
—
—
1.3e-02
4.7e-01
cases:14.92%
controls:13.23%
cases:7.68%
controls:4.73%
cases:1.73%
controls:0.39%
—
—
—
—
cases:4.58%
controls:4.52%
cases:20.99%
controls:14.20%
77
679
439
4455
40
245
481
4935
9
20
512
5160
—
—
23
227
479
4790
93
627
350
3790
temazepam; oral
N05CD07 [21604642]
7.3e-01
1.1e+00
—
—
—
8.2e-01
8.6e-01
cases:4.65%
controls:2.30%
cases:3.65%
controls:1.22%
—
—
—
—
—
—
cases:2.99%
controls:1.34%
cases:5.19%
controls:2.26%
24
118
492
5016
19
63
502
5117
—
—
—
15
67
487
4950
23
100
420
4317
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
9.7e-01
7.8e-01
—
—
—
1.0e+00
5.6e-01
cases:7.75%
controls:3.10%
cases:2.69%
controls:1.25%
—
—
—
—
—
—
cases:3.39%
controls:1.26%
cases:8.13%
controls:4.80%
40
159
476
4975
14
65
507
5115
—
—
—
17
63
485
4954
36
212
407
4205
Limited function/disability (N)
N28 [2002000733]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.58%
controls:0.23%
—
—
—
—
—
—
7
10
436
4407
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
5.7e-01
3.4e-01
—
—
2.0e+00
7.7e-01
4.7e-01
cases:4.26%
controls:2.45%
cases:2.11%
controls:1.51%
—
—
—
—
cases:1.35%
controls:0.19%
cases:4.18%
controls:1.97%
cases:9.26%
controls:6.00%
22
126
494
5008
11
78
510
5102
—
—
7
10
512
5166
21
99
481
4918
41
265
402
4152
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
4.2e-01
5.4e-01
—
—
2.0e+00
4.5e-01
6.3e-01
cases:4.65%
controls:3.12%
cases:2.88%
controls:1.70%
—
—
—
—
cases:1.35%
controls:0.19%
cases:2.79%
controls:1.79%
cases:5.19%
controls:2.83%
24
160
492
4974
15
88
506
5092
—
—
7
10
512
5166
14
90
488
4927
23
125
420
4292
Medication/prescr/renewal
-50 [2002000121]
2.0e+00
—
—
—
—
—
—
cases:1.36%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
7
10
509
5124
—
—
—
—
—
—
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
7.0e-01
2.0e+00
—
—
—
—
7.6e-01
cases:1.74%
controls:0.88%
cases:1.34%
controls:0.19%
—
—
—
—
—
—
—
—
cases:2.71%
controls:1.29%
9
45
507
5089
7
10
514
5170
—
—
—
—
12
57
431
4360
Moderate depressive episode with somatic syndrome
F32.11 [2000501981]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.29%
—
—
—
—
—
—
9
13
434
4404
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
—
—
—
—
—
1.9e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:1.59%
controls:0.24%
cases:1.81%
controls:0.43%
—
—
—
—
—
8
12
494
5005
8
19
435
4398
Bacteria [Presence] in Urine
87829-8 [36304419]
5.4e-01
1.0e+00
—
—
1.4e+00
8.9e-01
5.2e-01
cases:7.95%
controls:4.79%
cases:6.72%
controls:2.57%
—
—
—
—
cases:1.54%
controls:0.39%
cases:5.78%
controls:2.45%
cases:9.93%
controls:6.18%
41
246
475
4888
35
133
486
5047
—
—
8
20
511
5156
29
123
473
4894
44
273
399
4144
Ultrasound examination of lower leg veins
PH2AE [2001309451]
4.4e-01
1.9e+00
—
—
—
—
4.7e-01
cases:1.36%
controls:0.88%
cases:1.34%
controls:0.21%
—
—
—
—
—
—
—
—
cases:2.26%
controls:1.43%
7
45
509
5089
7
11
514
5169
—
—
—
—
10
63
433
4354
Cervical spine MRI examination with high intensity magnet
NA1BG [2001306990]
9.9e-01
1.9e+00
—
—
—
—
1.5e+00
cases:1.36%
controls:0.51%
cases:1.34%
controls:0.21%
—
—
—
—
—
—
—
—
cases:1.58%
controls:0.36%
7
26
509
5108
7
11
514
5169
—
—
—
—
7
16
436
4401
Removal of sutures
SPAT1153 [2001700254]
6.7e-02
1.0e+00
—
—
—
2.6e-01
8.5e-01
cases:4.65%
controls:4.36%
cases:2.88%
controls:1.08%
—
—
—
—
—
—
cases:1.39%
controls:1.08%
cases:7.22%
controls:3.21%
24
224
492
4910
15
56
506
5124
—
—
—
7
54
495
4963
32
142
411
4275
Insertion of intrauterine device
TLC00 [2001306647]
6.2e-01
-1.0e+50
—
—
—
—
1.8e+00
cases:0.97%
controls:0.53%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
cases:2.26%
controls:0.36%
5
27
511
5107
0
8
521
5172
—
—
—
—
10
16
433
4401
Scheduled procedure
ZXD10 [2001311387]
4.3e-01
1.0e+00
—
—
—
8.7e-01
8.1e-01
cases:9.11%
controls:6.14%
cases:4.41%
controls:1.62%
—
—
—
—
—
—
cases:2.99%
controls:1.28%
cases:7.22%
controls:3.35%
47
315
469
4819
23
84
498
5096
—
—
—
15
64
487
4953
32
148
411
4269
tizanidine; oral
M03BX02 [21604116]
3.6e-01
4.9e-01
1.3e+00
—
—
5.3e-01
5.3e-01
cases:17.64%
controls:12.99%
cases:6.53%
controls:4.11%
cases:2.50%
controls:0.69%
—
—
—
—
cases:6.97%
controls:4.23%
cases:18.28%
controls:11.64%
91
667
425
4467
34
213
487
4967
13
36
508
5144
—
—
35
212
467
4805
81
514
362
3903
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
8.0e-01
1.8e+00
—
—
—
1.6e+00
1.2e+00
cases:1.55%
controls:0.70%
cases:1.54%
controls:0.25%
—
—
—
—
—
—
cases:1.20%
controls:0.24%
cases:2.03%
controls:0.63%
8
36
508
5098
8
13
513
5167
—
—
—
6
12
496
5005
9
28
434
4389
Urology
34 [38004474]
5.4e-01
4.1e-01
—
—
—
9.0e-01
9.2e-01
cases:8.14%
controls:4.91%
cases:3.45%
controls:2.32%
—
—
—
—
—
—
cases:5.18%
controls:2.17%
cases:11.51%
controls:4.94%
42
252
474
4882
18
120
503
5060
—
—
—
26
109
476
4908
51
218
392
4199
Ultrasound measurement of residual urine
KC1EE [2001305918]
8.4e-01
—
—
—
—
1.8e+00
7.7e-01
cases:3.49%
controls:1.54%
—
—
—
—
—
—
—
—
cases:1.39%
controls:0.24%
cases:2.71%
controls:1.27%
18
79
498
5055
—
—
—
—
7
12
495
5005
12
56
431
4361
Senile macular degeneration (atrophic)(exudative)
H35.31 [2000502315]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.58%
controls:0.27%
—
—
—
—
—
—
7
12
436
4405
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
1.2e-01
9.6e-01
8.8e-01
—
—
5.7e-01
7.9e-01
cases:3.10%
controls:2.77%
cases:3.65%
controls:1.43%
cases:1.15%
controls:0.48%
—
—
—
—
cases:2.79%
controls:1.59%
cases:5.87%
controls:2.74%
16
142
500
4992
19
74
502
5106
6
25
515
5155
—
—
14
80
488
4937
26
121
417
4296
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
4.0e-01
8.6e-01
1.1e+00
—
1.0e+00
8.9e-01
3.9e-01
cases:6.59%
controls:4.50%
cases:5.18%
controls:2.26%
cases:0.96%
controls:0.33%
—
—
cases:1.16%
controls:0.43%
cases:4.98%
controls:2.11%
cases:10.16%
controls:7.13%
34
231
482
4903
27
117
494
5063
5
17
516
5163
—
6
22
513
5154
25
106
477
4911
45
315
398
4102
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
2.8e-01
1.9e-01
1.6e-01
—
1.7e+00
2.3e-01
1.1e-01
cases:27.52%
controls:22.38%
cases:13.82%
controls:11.72%
cases:1.54%
controls:1.31%
—
—
cases:5.78%
controls:1.06%
cases:13.75%
controls:11.22%
cases:31.60%
controls:29.27%
142
1149
374
3985
72
607
449
4573
8
68
513
5112
—
30
55
489
5121
69
563
433
4454
140
1293
303
3124
Depressive episode, unspecified
F32.9 [45571760]
3.6e-01
7.3e-01
—
—
—
1.7e+00
8.1e-01
cases:2.13%
controls:1.50%
cases:0.96%
controls:0.46%
—
—
—
—
—
—
cases:2.59%
controls:0.48%
cases:4.29%
controls:1.95%
11
77
505
5057
5
24
516
5156
—
—
—
13
24
489
4993
19
86
424
4331
propranolol; oral, parenteral
C07AA05 [21601670]
2.2e-01
6.8e-01
1.3e+00
—
1.6e+00
8.0e-01
9.1e-01
cases:4.46%
controls:3.62%
cases:3.84%
controls:1.99%
cases:1.15%
controls:0.33%
—
—
cases:1.54%
controls:0.33%
cases:4.58%
controls:2.11%
cases:9.48%
controls:4.05%
23
186
493
4948
20
103
501
5077
6
17
515
5163
—
8
17
511
5159
23
106
479
4911
42
179
401
4238
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
1.7e-01
4.2e-01
4.5e-01
—
1.3e+00
3.2e-01
2.7e-01
cases:27.71%
controls:24.48%
cases:18.62%
controls:13.03%
cases:2.11%
controls:1.35%
—
—
cases:5.59%
controls:1.62%
cases:17.53%
controls:13.31%
cases:38.15%
controls:31.97%
143
1257
373
3877
97
675
424
4505
11
70
510
5110
—
29
84
490
5092
88
668
414
4349
169
1412
274
3005
Migraine with aura [classical migraine]
G43.1 [45562086]
6.7e-01
1.7e+00
—
—
—
1.3e+00
7.2e-01
cases:1.55%
controls:0.80%
cases:1.54%
controls:0.29%
—
—
—
—
—
—
cases:1.59%
controls:0.44%
cases:2.26%
controls:1.11%
8
41
508
5093
8
15
513
5165
—
—
—
8
22
494
4995
10
49
433
4368
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
5.9e-01
9.6e-01
—
—
2.3e+00
1.2e+00
1.7e+00
cases:1.36%
controls:0.76%
cases:1.15%
controls:0.44%
—
—
—
—
cases:0.96%
controls:0.10%
cases:1.00%
controls:0.30%
cases:2.03%
controls:0.38%
7
39
509
5095
6
23
515
5157
—
—
5
5
514
5171
5
15
497
5002
9
17
434
4400
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
9.2e-01
1.7e+00
—
—
—
1.4e+00
8.6e-01
cases:1.74%
controls:0.70%
cases:1.73%
controls:0.33%
—
—
—
—
—
—
cases:1.59%
controls:0.40%
cases:2.93%
controls:1.27%
9
36
507
5098
9
17
512
5163
—
—
—
8
20
494
4997
13
56
430
4361
Audiometric test
21727005 [4071702]
7.4e-01
1.2e+00
—
—
—
1.7e+00
4.9e-01
cases:3.88%
controls:1.89%
cases:1.73%
controls:0.52%
—
—
—
—
—
—
cases:2.99%
controls:0.58%
cases:3.61%
controls:2.24%
20
97
496
5037
9
27
512
5153
—
—
—
15
29
487
4988
16
99
427
4318
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
1.7e+00
—
-1.0e+50
—
-1.0e+50
—
1.8e+00
cases:2.33%
controls:0.45%
—
—
cases:0.00%
controls:0.10%
—
—
cases:0.00%
controls:0.10%
—
—
cases:1.35%
controls:0.23%
12
23
504
5111
—
0
5
521
5175
—
0
5
519
5171
—
6
10
437
4407
topiramate; oral
N03AX11 [21604433]
1.1e+00
1.9e+00
—
—
—
1.9e+00
1.6e+00
cases:1.55%
controls:0.51%
cases:1.15%
controls:0.17%
—
—
—
—
—
—
cases:1.20%
controls:0.18%
cases:2.03%
controls:0.41%
8
26
508
5108
6
9
515
5171
—
—
—
6
9
496
5008
9
18
434
4399
Telehealth
OMOP5556618 [722455]
2.3e-01
4.6e-01
7.9e-01
—
7.6e-01
6.7e-01
4.8e-01
cases:25.39%
controls:21.33%
cases:14.20%
controls:9.42%
cases:3.45%
controls:1.60%
—
—
cases:2.70%
controls:1.28%
cases:14.94%
controls:8.23%
cases:28.89%
controls:20.01%
131
1095
385
4039
74
488
447
4692
18
83
503
5097
—
14
66
505
5110
75
413
427
4604
128
884
315
3533
Blepharitis
H01.0 [45533180]
1.6e+00
—
—
—
—
—
6.3e-01
cases:1.94%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:1.35%
controls:0.72%
10
20
506
5114
—
—
—
—
—
6
32
437
4385
Ear microscopy
UDC00 [2001301558]
5.1e-01
1.6e+00
—
—
—
1.4e+00
6.0e-01
cases:1.55%
controls:0.93%
cases:1.73%
controls:0.35%
—
—
—
—
—
—
cases:1.00%
controls:0.26%
cases:1.81%
controls:1.00%
8
48
508
5086
9
18
512
5162
—
—
—
5
13
497
5004
8
44
435
4373
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
2.6e-01
1.6e-01
-5.9e-03
—
1.6e+00
1.9e-01
1.0e-01
cases:28.88%
controls:23.92%
cases:16.31%
controls:14.19%
cases:1.73%
controls:1.74%
—
—
cases:7.13%
controls:1.53%
cases:16.33%
controls:13.91%
cases:37.02%
controls:34.66%
149
1228
367
3906
85
735
436
4445
9
90
512
5090
—
37
79
482
5097
82
698
420
4319
164
1531
279
2886
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
—
—
—
—
—
1.6e+00
8.0e-01
—
—
—
—
—
—
—
—
—
—
cases:2.19%
controls:0.46%
cases:2.93%
controls:1.34%
—
—
—
—
—
11
23
491
4994
13
59
430
4358
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
7.0e-01
—
—
—
—
1.6e+00
3.8e-01
cases:1.55%
controls:0.78%
—
—
—
—
—
—
—
—
cases:1.79%
controls:0.38%
cases:1.35%
controls:0.93%
8
40
508
5094
—
—
—
—
9
19
493
4998
6
41
437
4376
Depressive episode
F32 [45595904]
6.6e-01
—
—
—
—
—
1.6e+00
cases:1.16%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.43%
6
31
510
5103
—
—
—
—
—
9
19
434
4398
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
3.2e-01
3.2e-01
—
—
1.3e+00
9.8e-01
5.7e-01
cases:9.30%
controls:6.95%
cases:4.61%
controls:3.38%
—
—
—
—
cases:1.54%
controls:0.44%
cases:8.17%
controls:3.23%
cases:16.93%
controls:10.30%
48
357
468
4777
24
175
497
5005
—
—
8
23
511
5153
41
162
461
4855
75
455
368
3962
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
2.7e-01
1.5e-01
7.6e-02
—
1.6e+00
1.9e-01
1.1e-01
cases:28.68%
controls:23.43%
cases:15.55%
controls:13.67%
cases:1.73%
controls:1.60%
—
—
cases:6.74%
controls:1.51%
cases:15.94%
controls:13.57%
cases:36.57%
controls:34.03%
148
1203
368
3931
81
708
440
4472
9
83
512
5097
—
35
78
484
5098
80
681
422
4336
162
1503
281
2914
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
8.5e-01
5.8e-01
—
—
—
1.5e+00
1.5e+00
cases:2.91%
controls:1.27%
cases:1.34%
controls:0.75%
—
—
—
—
—
—
cases:1.20%
controls:0.26%
cases:4.51%
controls:1.00%
15
65
501
5069
7
39
514
5141
—
—
—
6
13
496
5004
20
44
423
4373
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
2.4e-01
1.7e-01
2.2e-01
—
1.5e+00
1.6e-01
1.1e-01
cases:29.84%
controls:25.09%
cases:18.23%
controls:15.83%
cases:2.30%
controls:1.85%
—
—
cases:7.51%
controls:1.70%
cases:17.93%
controls:15.75%
cases:38.60%
controls:36.00%
154
1288
362
3846
95
820
426
4360
12
96
509
5084
—
39
88
480
5088
90
790
412
4227
171
1590
272
2827
Genetic counselling
Z31.5 [45590715]
3.9e-01
—
—
—
—
—
1.5e+00
cases:1.55%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
cases:3.39%
controls:0.75%
8
54
508
5080
—
—
—
—
—
15
33
428
4384
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
2.7e-01
—
-1.0e+50
—
—
1.6e+00
1.5e+00
cases:0.97%
controls:0.74%
—
—
cases:0.00%
controls:0.10%
—
—
—
—
cases:1.20%
controls:0.24%
cases:2.26%
controls:0.50%
5
38
511
5096
—
0
5
521
5175
—
—
6
12
496
5005
10
22
433
4395
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
4.4e-01
8.3e-01
—
—
—
1.5e+00
5.1e-01
cases:2.52%
controls:1.64%
cases:1.54%
controls:0.68%
—
—
—
—
—
—
cases:2.59%
controls:0.58%
cases:2.93%
controls:1.79%
13
84
503
5050
8
35
513
5145
—
—
—
13
29
489
4988
13
79
430
4338
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
1.4e-01
7.0e-01
1.1e+00
—
1.1e+00
8.1e-01
4.7e-01
cases:8.91%
controls:7.85%
cases:6.72%
controls:3.44%
cases:1.34%
controls:0.46%
—
—
cases:1.35%
controls:0.44%
cases:5.78%
controls:2.65%
cases:12.19%
controls:7.99%
46
403
470
4731
35
178
486
5002
7
24
514
5156
—
7
23
512
5153
29
133
473
4884
54
353
389
4064
Intravenous administration of medicine
SPAT1255 [2001700356]
6.9e-01
—
—
—
—
—
1.5e+00
cases:1.16%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:2.71%
controls:0.63%
6
30
510
5104
—
—
—
—
—
12
28
431
4389
Foot and toes X-ray examination
NH3AA [2001308267]
8.7e-01
—
—
—
—
—
1.4e+00
cases:1.94%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:3.16%
controls:0.77%
10
42
506
5092
—
—
—
—
—
14
34
429
4383
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.0e-01
5.9e-01
5.8e-01
—
9.9e-01
8.4e-01
3.5e-01
cases:11.24%
controls:7.83%
cases:8.45%
controls:4.85%
cases:1.34%
controls:0.75%
—
—
cases:2.31%
controls:0.87%
cases:10.76%
controls:4.94%
cases:19.86%
controls:14.83%
58
402
458
4732
44
251
477
4929
7
39
514
5141
—
12
45
507
5131
54
248
448
4769
88
655
355
3762
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
3.9e-01
6.1e-01
5.6e-01
—
9.7e-01
8.2e-01
3.7e-01
cases:11.63%
controls:8.20%
cases:8.64%
controls:4.86%
cases:1.34%
controls:0.77%
—
—
cases:2.31%
controls:0.89%
cases:10.76%
controls:5.04%
cases:20.09%
controls:14.74%
60
421
456
4713
45
252
476
4928
7
40
514
5140
—
12
46
507
5130
54
253
448
4764
89
651
354
3766
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
5.8e-01
8.5e-01
1.3e+00
—
—
7.3e-01
3.8e-01
cases:9.69%
controls:5.69%
cases:4.61%
controls:2.03%
cases:0.96%
controls:0.25%
—
—
—
—
cases:4.58%
controls:2.25%
cases:8.35%
controls:5.84%
50
292
466
4842
24
105
497
5075
5
13
516
5167
—
—
23
113
479
4904
37
258
406
4159
Microorganisms panel - Urine sediment
58435-9 [40761536]
8.1e-01
1.2e+00
—
—
—
1.4e+00
6.7e-01
cases:3.10%
controls:1.40%
cases:2.11%
controls:0.68%
—
—
—
—
—
—
cases:2.59%
controls:0.64%
cases:2.93%
controls:1.52%
16
72
500
5062
11
35
510
5145
—
—
—
13
32
489
4985
13
67
430
4350
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
1.2e+00
—
—
—
—
—
1.4e+00
cases:2.13%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.61%
11
32
505
5102
—
—
—
—
—
11
27
432
4390
Monitored bed care
WX892 [2001310850]
1.4e+00
1.6e+00
—
—
—
—
9.2e-01
cases:2.13%
controls:0.53%
cases:0.96%
controls:0.19%
—
—
—
—
—
—
—
—
cases:1.58%
controls:0.63%
11
27
505
5107
5
10
516
5170
—
—
—
—
7
28
436
4389
Acute tubulo-interstitial nephritis
N10 [45543856]
1.2e-01
—
—
—
—
1.4e+00
5.6e-01
cases:1.36%
controls:1.21%
—
—
—
—
—
—
—
—
cases:1.99%
controls:0.50%
cases:2.93%
controls:1.70%
7
62
509
5072
—
—
—
—
10
25
492
4992
13
75
430
4342
Fungus identified in Specimen by Culture
580-1 [3000494]
2.3e-01
1.8e-01
—
—
—
1.4e+00
2.5e-01
cases:2.33%
controls:1.85%
cases:1.15%
controls:0.97%
—
—
—
—
—
—
cases:1.99%
controls:0.50%
cases:3.16%
controls:2.47%
12
95
504
5039
6
50
515
5130
—
—
—
10
25
492
4992
14
109
429
4308
carbamazepine; oral, rectal
N03AF01 [21604417]
5.6e-01
9.2e-01
—
—
—
1.2e+00
1.4e+00
cases:1.36%
controls:0.78%
cases:0.96%
controls:0.39%
—
—
—
—
—
—
cases:1.00%
controls:0.30%
cases:2.26%
controls:0.57%
7
40
509
5094
5
20
516
5160
—
—
—
5
15
497
5002
10
25
433
4392
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
6.5e-01
—
—
—
—
1.4e+00
1.4e+00
cases:2.13%
controls:1.13%
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.30%
cases:2.26%
controls:0.57%
11
58
505
5076
—
—
—
—
6
15
496
5002
10
25
433
4392
Psychiatric monitoring contact
IGY02 [2001304322]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.26%
controls:0.57%
—
—
—
—
—
—
10
25
433
4392
Other and unspecified convulsions
R56.8 [45602033]
1.4e+00
—
—
—
—
—
1.3e+00
cases:1.94%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:2.03%
controls:0.59%
10
25
506
5109
—
—
—
—
—
9
26
434
4391
Respiratory and circulatory monitoring
WX700 [2001310817]
7.0e-01
1.4e+00
—
—
—
8.1e-01
5.2e-01
cases:3.68%
controls:1.87%
cases:3.26%
controls:0.83%
—
—
—
—
—
—
cases:1.59%
controls:0.72%
cases:2.48%
controls:1.49%
19
96
497
5038
17
43
504
5137
—
—
—
8
36
494
4981
11
66
432
4351
Other specified special examinations
Z01.8 [45581003]
6.4e-01
1.4e+00
—
—
—
9.3e-01
5.2e-01
cases:4.84%
controls:2.61%
cases:3.65%
controls:0.95%
—
—
—
—
—
—
cases:2.39%
controls:0.96%
cases:5.64%
controls:3.42%
25
134
491
5000
19
49
502
5131
—
—
—
12
48
490
4969
25
151
418
4266
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
5.9e-01
1.4e+00
—
—
—
1.2e+00
7.1e-01
cases:1.74%
controls:0.97%
cases:2.69%
controls:0.69%
—
—
—
—
—
—
cases:2.19%
controls:0.68%
cases:2.93%
controls:1.47%
9
50
507
5084
14
36
507
5144
—
—
—
11
34
491
4983
13
65
430
4352
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
6.3e-01
4.1e-01
—
—
—
1.3e+00
6.1e-01
cases:2.33%
controls:1.25%
cases:1.73%
controls:1.16%
—
—
—
—
—
—
cases:2.19%
controls:0.58%
cases:2.71%
controls:1.49%
12
64
504
5070
9
60
512
5120
—
—
—
11
29
491
4988
12
66
431
4351
Immunohistochemistry procedure
117617002 [4035726]
3.7e-01
1.3e+00
—
—
—
—
8.2e-01
cases:1.74%
controls:1.21%
cases:2.11%
controls:0.56%
—
—
—
—
—
—
—
—
cases:1.58%
controls:0.70%
9
62
507
5072
11
29
510
5151
—
—
—
—
7
31
436
4386
Chest symptom/complaint
L04 [2002000629]
1.3e+00
—
—
—
—
—
—
cases:2.33%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
12
32
504
5102
—
—
—
—
—
—
Infiltration anesthesia
WX110 [2001310767]
1.8e-01
7.4e-01
4.9e-01
—
5.3e-01
2.8e-01
5.8e-01
cases:20.54%
controls:17.76%
cases:13.63%
controls:6.99%
cases:1.54%
controls:0.95%
—
—
cases:1.73%
controls:1.02%
cases:9.16%
controls:7.12%
cases:30.47%
controls:19.70%
106
912
410
4222
71
362
450
4818
8
49
513
5131
—
9
53
510
5123
46
357
456
4660
135
870
308
3547
pH of Specimen
17433-4 [3019225]
3.1e-01
1.1e+00
—
—
1.7e+00
1.3e+00
8.9e-01
cases:2.71%
controls:2.01%
cases:2.11%
controls:0.71%
—
—
—
—
cases:0.96%
controls:0.17%
cases:2.19%
controls:0.60%
cases:3.84%
controls:1.61%
14
103
502
5031
11
37
510
5143
—
—
5
9
514
5167
11
30
491
4987
17
71
426
4346
fluticasone furoate; nasal
R01AD12 [21605053]
5.7e-01
6.3e-01
6.1e-01
—
—
7.5e-01
2.9e-01
cases:13.57%
controls:8.18%
cases:5.57%
controls:3.05%
cases:0.96%
controls:0.52%
—
—
—
—
cases:6.77%
controls:3.33%
cases:11.29%
controls:8.67%
70
420
446
4714
29
158
492
5022
5
27
516
5153
—
—
34
167
468
4850
50
383
393
4034
fluticasone; nasal
R01AD08 [21605050]
5.7e-01
6.3e-01
6.1e-01
—
—
7.5e-01
2.9e-01
cases:13.57%
controls:8.18%
cases:5.57%
controls:3.05%
cases:0.96%
controls:0.52%
—
—
—
—
cases:6.77%
controls:3.33%
cases:11.29%
controls:8.67%
70
420
446
4714
29
158
492
5022
5
27
516
5153
—
—
34
167
468
4850
50
383
393
4034
alendronic acid; oral
M05BA04 [21604152]
7.2e-01
—
—
—
—
1.0e+00
1.3e+00
cases:1.55%
controls:0.76%
—
—
—
—
—
—
—
—
cases:1.39%
controls:0.50%
cases:2.71%
controls:0.75%
8
39
508
5095
—
—
—
—
7
25
495
4992
12
33
431
4384
Bacterial infection, unspecified
A49.9 [45590816]
—
1.2e+00
—
—
—
9.7e-01
1.3e+00
—
—
cases:1.15%
controls:0.37%
—
—
—
—
—
—
cases:1.00%
controls:0.38%
cases:2.71%
controls:0.75%
—
6
19
515
5161
—
—
—
5
19
497
4998
12
33
431
4384
mirtazapine; oral
N06AX11 [21604740]
6.0e-01
6.1e-01
7.2e-01
—
4.6e-01
5.4e-01
7.0e-01
cases:8.91%
controls:5.10%
cases:5.18%
controls:2.90%
cases:1.34%
controls:0.66%
—
—
cases:1.16%
controls:0.73%
cases:4.98%
controls:2.97%
cases:12.64%
controls:6.72%
46
262
470
4872
27
150
494
5030
7
34
514
5146
—
6
38
513
5138
25
149
477
4868
56
297
387
4120
Pneumonia, unspecified
J18.9 [45601123]
7.0e-01
4.9e-01
—
—
—
1.3e+00
4.7e-01
cases:5.23%
controls:2.67%
cases:1.73%
controls:1.06%
—
—
—
—
—
—
cases:3.19%
controls:0.90%
cases:6.09%
controls:3.89%
27
137
489
4997
9
55
512
5125
—
—
—
16
45
486
4972
27
172
416
4245
12 lead EKG panel
34534-8 [3044889]
1.8e-01
4.2e-01
7.4e-01
—
1.3e+00
4.2e-01
3.6e-01
cases:16.67%
controls:14.26%
cases:10.75%
controls:7.32%
cases:1.92%
controls:0.93%
—
—
cases:3.47%
controls:0.99%
cases:9.96%
controls:6.78%
cases:24.60%
controls:18.59%
86
732
430
4402
56
379
465
4801
10
48
511
5132
—
18
51
501
5125
50
340
452
4677
109
821
334
3596
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
4.0e-01
6.8e-01
5.8e-01
—
—
7.4e-01
5.3e-01
cases:10.66%
controls:7.40%
cases:5.18%
controls:2.68%
cases:0.96%
controls:0.54%
—
—
—
—
cases:6.57%
controls:3.25%
cases:12.64%
controls:7.86%
55
380
461
4754
27
139
494
5041
5
28
516
5152
—
—
33
163
469
4854
56
347
387
4070
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
2.8e-01
2.7e-01
4.6e-02
—
1.3e+00
2.6e-01
1.9e-01
cases:24.42%
controls:19.61%
cases:16.70%
controls:13.22%
cases:1.92%
controls:1.83%
—
—
cases:5.78%
controls:1.72%
cases:16.73%
controls:13.43%
cases:34.76%
controls:30.61%
126
1007
390
4127
87
685
434
4495
10
95
511
5085
—
30
89
489
5087
84
674
418
4343
154
1352
289
3065
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
6.3e-01
—
—
—
—
9.2e-01
1.2e+00
cases:1.74%
controls:0.93%
—
—
—
—
—
—
—
—
cases:1.20%
controls:0.48%
cases:3.16%
controls:0.93%
9
48
507
5086
—
—
—
—
6
24
496
4993
14
41
429
4376
Hyperplasia of prostate
N40 [45563015]
-5.2e-03
8.5e-02
—
—
—
1.2e+00
3.7e-01
cases:2.71%
controls:2.73%
cases:1.34%
controls:1.24%
—
—
—
—
—
—
cases:3.39%
controls:1.00%
cases:3.84%
controls:2.69%
14
140
502
4994
7
64
514
5116
—
—
—
17
50
485
4967
17
119
426
4298
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
6.0e-01
1.2e+00
—
—
—
1.2e+00
1.2e+00
cases:2.52%
controls:1.40%
cases:2.11%
controls:0.62%
—
—
—
—
—
—
cases:2.39%
controls:0.74%
cases:5.87%
controls:1.79%
13
72
503
5062
11
32
510
5148
—
—
—
12
37
490
4980
26
79
417
4338
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
6.7e-01
1.2e+00
-1.0e+50
—
2.0e+00
1.1e+00
6.4e-01
cases:2.52%
controls:1.31%
cases:2.69%
controls:0.81%
cases:0.00%
controls:0.21%
—
—
cases:0.96%
controls:0.14%
cases:1.99%
controls:0.66%
cases:3.61%
controls:1.95%
13
67
503
5067
14
42
507
5138
0
11
521
5169
—
5
7
514
5169
10
33
492
4984
16
86
427
4331
nepafenac
S01BC10 [21603648]
1.2e+00
—
—
—
—
1.5e+00
3.3e-01
cases:2.52%
controls:0.76%
—
—
—
—
—
—
—
—
cases:1.39%
controls:0.32%
cases:2.03%
controls:1.47%
13
39
503
5095
—
—
—
—
7
16
495
5001
9
65
434
4352
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
2.6e-01
2.7e-01
—
—
—
1.2e+00
5.8e-01
cases:2.52%
controls:1.95%
cases:1.54%
controls:1.18%
—
—
—
—
—
—
cases:3.98%
controls:1.22%
cases:5.19%
controls:2.99%
13
100
503
5034
8
61
513
5119
—
—
—
20
61
482
4956
23
132
420
4285
acetylsalicylic acid, combinations excl. psycholeptics
N02BA51 [21604320]
5.7e-01
1.2e+00
—
—
1.3e+00
1.0e+00
1.1e+00
cases:1.74%
controls:0.99%
cases:2.30%
controls:0.69%
—
—
—
—
cases:1.16%
controls:0.31%
cases:1.99%
controls:0.74%
cases:2.48%
controls:0.82%
9
51
507
5083
12
36
509
5144
—
—
6
16
513
5160
10
37
492
4980
11
36
432
4381
platelet aggregation inhibitors excl. heparin - combinations
B01AC30 [21601005]
5.7e-01
1.2e+00
—
—
1.3e+00
1.0e+00
1.1e+00
cases:1.74%
controls:0.99%
cases:2.30%
controls:0.69%
—
—
—
—
cases:1.16%
controls:0.31%
cases:1.99%
controls:0.74%
cases:2.48%
controls:0.82%
9
51
507
5083
12
36
509
5144
—
—
6
16
513
5160
10
37
492
4980
11
36
432
4381

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
59
110
5.88
30.90
1.8
2.4
—
—
—
0
0
257
1341
2.70
28.64
2.9
2.1
189.70
241.04
u/l
0.34
247
1272
49
121
4.34
18.40
1.9
2.3
15.78
12.67
e6/l
0.12
32
86
49
122
4.31
18.21
1.9
2.3
178.18
133.43
e6/l
0.10
34
91
341
2335
2.19
17.49
10.7
8.8
1.22
1.21
mmol/l
0.42
301
2039
296
1989
2.04
15.12
5.9
5.7
35.96
36.36
g/l
0.59
268
1880
311
2128
2.04
15.09
10.0
8.8
1.22
1.22
mmol/l
0.10
290
1978
25
25
10.41
13.10
1.1
1.3
132.00
143.46
nmol/l
0.44
25
25
96
445
2.40
12.38
3.6
3.0
9.98
10.03
g/l
0.05
90
412
280
1948
1.88
11.91
14.8
10.6
1.18
1.18
inr
0.01
233
1598
28
65
4.48
11.35
2.2
3.2
—
—
—
0
0
354
2678
1.88
11.32
9.1
7.3
1.90
1.99
e9/l
0.71
309
2356
333
2477
1.86
11.17
8.9
7.4
28.34
29.38
%
0.96
321
2368
255
1747
1.85
11.17
8.7
7.5
—
—
—
0
0
109
557
2.19
11.11
1.9
2.3
360.06
379.44
nmol/l
0.47
101
531
329
2444
1.84
11.02
8.9
7.3
57.34
55.91
%
1.34
322
2351
155
907
1.98
10.98
4.1
2.9
552.81
547.66
mosm/kgh2o
0.10
141
792
347
2631
1.84
10.77
9.2
7.3
0.04
0.04
e9/l
0.23
302
2253
346
2623
1.84
10.72
9.2
7.3
0.57
0.57
e9/l
0.15
301
2243
329
2457
1.83
10.70
7.3
6.9
12.74
13.27
umol/l
0.15
310
2342
207
1343
1.86
10.68
3.7
2.9
—
—
—
0
0
324
2416
1.81
10.51
9.0
7.6
8.59
8.66
%
0.16
311
2285
454
3778
2.09
10.39
4.5
4.3
14.81
14.64
pmol/l
0.71
421
3510
359
2781
1.82
10.06
7.3
6.3
6.40
6.53
mmol/l
0.67
342
2609
352
2714
1.81
9.98
9.6
7.7
0.19
0.19
e9/l
0.04
308
2359
73
330
2.39
9.88
2.5
2.9
65.40
66.97
g/l
0.84
68
313
320
2415
1.76
9.60
9.1
7.5
0.69
0.68
%
0.11
308
2277
71
322
2.38
9.54
1.5
1.3
71.00
32.44
au/ml
—
6
20
320
2418
1.76
9.53
9.1
7.5
2.81
2.84
%
0.08
308
2285
367
2898
1.78
9.24
11.8
10.5
4.13
4.01
e9/l
0.30
318
2506
196
1298
1.79
9.17
1.9
1.6
19.95
21.05
nmol/l
0.44
176
1105
60
260
2.46
8.90
1.8
2.6
—
—
—
0
0
201
1356
1.75
8.74
4.5
3.2
0.56
0.37
e6/l
0.26
156
969
30
91
3.43
8.46
1.2
1.2
—
—
—
0
0
208
1428
1.73
8.44
3.0
2.6
54.35
62.69
u/l
1.05
189
1333
73
356
2.21
8.26
2.7
2.4
11.00
20.15
au/ml
—
8
28
233
1681
1.66
7.68
4.1
3.5
29.48
31.90
u/l
0.68
220
1596
99
557
1.94
7.62
7.2
7.5
7.38
7.38
ph
0.02
67
313
220
1566
1.67
7.62
4.6
3.4
31.21
92.73
e6/l
0.77
177
1172
497
4422
2.15
7.41
5.9
5.3
1.87
1.88
mu/l
0.03
469
4144
161
1062
1.73
7.37
3.1
2.8
4.19
6.14
e6/l
1.22
149
961
114
682
1.84
7.26
9.9
8.2
1.09
1.12
mmol/l
0.35
106
643
419
3546
1.73
7.15
9.5
8.0
82.89
82.64
u/l
0.03
402
3367
194
1355
1.66
7.13
5.8
4.1
7.40
7.40
ph
1.54
143
947
19
34
5.74
7.12
1.1
1.2
0.59
0.54
ratio
0.30
11
17
218
1574
1.63
7.00
3.7
3.3
2.37
2.36
mmol/l
0.84
195
1440
281
2165
1.60
6.86
3.5
2.8
80.44
75.00
nmol/l
2.13
260
1993
106
633
1.83
6.76
6.7
9.8
104.38
104.36
mmol/l
0.01
106
633
109
658
1.82
6.71
2.0
1.7
959.10
1186.47
nmol/l
2.13
82
508
186
1303
1.64
6.68
4.6
3.2
—
0.00
estimate
—
0
5
9
5
18.25
6.28
1.1
1.0
—
—
—
0
0
519
4753
2.34
6.28
24.8
16.7
139.56
139.65
mmol/l
0.37
512
4662
519
4760
2.32
6.13
25.1
16.9
3.94
3.96
mmol/l
0.60
509
4655
172
1203
1.62
6.13
4.6
4.1
—
—
—
0
0
241
1833
1.55
5.96
5.8
4.1
71.75
74.14
e6/l
0.03
179
1243
484
4343
1.87
5.89
5.2
4.7
5.81
5.83
mmol/l
0.17
449
4029
21
65
3.32
5.78
2.1
3.0
43.61
38.76
%
0.86
21
65
16
41
3.99
5.74
2.6
3.4
0.10
0.55
e9/l
—
9
17
67
364
1.95
5.68
2.7
1.8
1.05
1.53
g/l
1.51
62
342
51
251
2.14
5.65
4.7
7.5
0.60
0.62
%
0.11
51
251
179
1290
1.57
5.53
2.4
2.3
3.19
2.76
mg/l
0.74
155
1128
34
143
2.47
5.41
2.1
2.0
206.72
352.97
ug/l
0.90
34
133
15
30
5.11
5.28
1.2
1.1
1872.00
1717.50
miu/ml
0.17
15
30
82
497
1.76
4.93
11.2
11.9
—
—
—
0
0
285
2324
1.46
4.66
13.4
11.5
0.00
0.01
e9/l
0.57
228
1866
9
11
8.29
4.57
1.0
1.0
4.96
5.10
mg/g
—
9
11
245
1947
1.46
4.55
2.6
2.0
96.59
97.43
pmol/l
0.10
156
1020
313
2607
1.46
4.53
5.6
3.8
0.00
3.00
estimate
0.50
73
542
8
8
10.12
4.53
1.8
1.1
79.13
86.50
umol/l
—
8
8
385
3339
1.49
4.52
4.4
3.5
45.29
43.72
u/l
0.14
362
3176
96
623
1.65
4.49
2.8
1.7
—
—
—
0
0
63
363
1.83
4.48
7.2
5.2
100.33
76.96
ng/l
1.10
55
331
115
784
1.59
4.41
4.6
3.0
1.84
2.13
e6/l
0.23
58
371
116
795
1.58
4.34
3.3
2.6
13.05
13.58
umol/l
0.33
107
748
7
6
11.79
4.28
1.4
1.0
—
—
—
0
0
125
877
1.55
4.22
1.7
1.7
463.01
440.34
pmol/l
0.45
105
749
259
2103
1.43
4.18
4.7
3.4
6.42
6.20
ph
2.07
133
1172
167
1248
1.48
4.18
1.7
1.5
2.12
2.21
g/l
0.31
115
755
312
2623
1.43
4.14
5.6
3.8
0.00
0.60
estimate
0.52
65
514
122
856
1.54
4.11
2.7
2.6
2.47
2.44
mmol/l
1.67
103
772
201
1564
1.45
4.06
3.8
3.6
7.21
8.00
mmol/l
1.56
181
1344
107
731
1.57
4.05
1.3
1.4
600.00
442.32
titre
0.46
22
155
512
4787
1.86
3.93
21.9
14.5
21.93
22.32
mg/l
0.09
430
3834
306
2580
1.41
3.90
5.5
3.8
0.00
0.00
estimate
0.50
73
542
77
491
1.66
3.85
8.7
11.5
7.40
7.41
ph
0.44
41
265
76
483
1.66
3.85
8.7
11.6
0.81
0.87
mmol/l
0.04
65
407
7
8
8.84
3.78
1.4
4.1
—
—
—
0
0
161
1216
1.46
3.76
3.1
3.7
1049.88
1092.16
ng/l
0.06
141
1031
36
183
2.03
3.72
1.3
1.3
—
3.54
—
0
8
269
2231
1.40
3.70
3.3
2.8
—
—
estimate
—
0
0
199
1568
1.42
3.68
3.0
2.4
—
—
—
0
0
83
547
1.61
3.65
2.9
3.6
1.85
1.71
%
0.56
75
504
57
340
1.75
3.64
4.9
3.8
1.23
1.23
mmol/l
0.27
45
290
119
852
1.50
3.62
4.3
3.9
208.56
534.32
ng/l
1.00
91
594
66
412
1.68
3.58
3.1
3.4
73.59
70.59
e9/l
0.22
53
293
7
9
7.86
3.56
1.0
1.4
68.71
58.67
ug/l
—
7
9
526
4984
1.99
3.52
15.3
11.5
26.47
26.46
u/l
0.00
514
4867
13
37
3.57
3.42
2.2
2.8
44.17
39.33
%
—
6
17
27
128
2.17
3.35
3.1
3.0
1.88
2.45
index
0.16
16
71
202
1618
1.39
3.33
3.9
3.4
33.98
30.41
ng/l
0.11
150
1057
36
191
1.95
3.32
5.3
5.0
220.00
288.52
mg/l
0.32
23
95
106
755
1.50
3.30
3.2
2.6
2.37
2.37
g/l
0.02
97
703
174
1361
1.40
3.30
4.4
4.2
8.40
8.07
mg/mmol
0.04
115
868
24
110
2.23
3.23
6.2
4.2
1.36
2.69
ratio
1.05
16
62
98
691
1.51
3.20
3.3
2.6
20.82
23.03
%
1.17
92
654
7
11
6.43
3.19
1.1
8.0
—
—
—
0
0
20
85
2.40
3.18
1.8
1.8
29.26
27.28
ng/l
0.08
20
85
67
436
1.61
3.11
1.4
1.5
—
—
—
0
0
170
1336
1.39
3.11
3.6
3.6
52.32
51.15
mg/l
0.03
112
885
190
1521
1.38
3.11
6.6
6.6
—
—
—
0
0
12
37
3.29
2.95
1.2
1.1
—
—
—
0
0
34
186
1.88
2.90
2.0
1.6
1.23
1.17
g/l
0.58
34
180
150
1181
1.37
2.66
5.0
3.7
—
0.18
—
0
11
94
682
1.45
2.66
1.7
1.6
—
—
—
0
0
483
4533
1.49
2.63
5.2
4.8
4.54
4.66
mmol/l
1.69
451
4268
288
2499
1.31
2.62
3.7
3.2
149.92
98.59
ug/l
0.92
274
2361
7
15
4.71
2.60
2.0
2.5
30.71
25.27
%
—
7
15
516
4916
1.67
2.60
18.5
12.4
—
—
—
0
0
89
642
1.46
2.60
1.3
1.2
—
—
—
0
0
16
68
2.39
2.57
1.7
1.3
296.36
289.65
mu/l
0.04
11
55
5
7
7.19
2.55
1.0
1.4
1.84
1.83
umol/24h
—
5
7
58
387
1.56
2.45
6.3
4.2
7.37
7.33
ph
1.45
44
273
35
205
1.75
2.43
2.3
1.8
9.17
8.36
u/l
0.10
22
151
456
4253
1.40
2.39
6.5
5.8
38.10
38.56
mmol/mol
0.58
421
4025
34
199
1.75
2.37
2.8
1.8
—
—
—
0
0
52
341
1.58
2.37
1.3
1.2
—
—
—
0
0
49
317
1.60
2.36
1.2
1.2
—
20.11
—
0
9
8
203
0.39
2.33
1.0
1.1
1.54
1.55
g/l
—
8
203
17
78
2.22
2.33
3.3
3.6
2.01
2.47
mmol/l
—
8
46
64
443
1.50
2.30
9.9
7.4
7.41
7.41
ph
0.15
54
345
30
171
1.80
2.29
1.5
1.3
—
—
—
0
0
6
13
4.65
2.27
1.3
1.8
—
—
—
0
0
92
685
1.41
2.27
2.0
2.1
—
—
—
0
0
172
1416
1.31
2.22
5.9
3.9
0.01
0.01
estimate
0.24
69
511
459
4302
1.38
2.20
4.3
4.1
1.29
1.26
mmol/l
0.46
425
4016
484
4578
1.43
2.18
5.8
5.4
2.66
2.75
mmol/l
1.50
451
4297
542
5265
2.08
2.14
33.0
22.1
254.65
255.95
e9/l
0.17
531
5148
51
343
1.54
2.10
10.3
7.7
—
—
—
0
0
542
5268
2.06
2.09
32.9
22.1
4.51
4.53
e12/l
0.63
532
5133
8
194
0.40
2.08
1.0
1.1
—
0.70
—
0
21
542
5269
2.05
2.07
33.0
22.1
6.86
6.73
e9/l
0.66
532
5133
74
541
1.42
2.03
1.4
1.4
—
—
—
0
0
17
83
2.08
2.03
1.2
1.8
—
—
—
0
0
24
133
1.84
2.02
1.2
1.3
—
—
—
0
0
57
399
1.48
1.96
5.8
5.5
0.67
0.48
%
0.50
18
123
165
1374
1.28
1.92
1.6
1.4
0.94
1.61
u/ml
1.02
40
357
9
34
2.67
1.87
1.0
3.3
9551.89
761.88
u/ml
—
9
34
37
238
1.59
1.86
6.0
6.9
—
—
—
0
0
11
46
2.42
1.86
1.9
2.5
10.17
15.06
index
—
6
33
9
35
2.60
1.80
2.0
1.6
—
—
—
0
0
7
23
3.07
1.80
1.0
1.8
—
—
—
0
0
8
29
2.78
1.79
1.1
1.2
—
—
—
0
0
6
18
3.36
1.75
2.0
1.2
0.57
0.47
e9/l
—
6
18
135
1109
1.29
1.74
2.0
2.3
1.33
1.27
mg/l
0.07
102
868
475
4516
1.35
1.74
5.2
4.7
1.42
1.46
mmol/l
1.20
445
4238
54
384
1.45
1.74
1.4
1.4
—
—
—
0
0
25
148
1.72
1.73
1.2
1.3
—
95.71
—
0
14
7
24
2.94
1.72
1.6
1.9
—
—
—
0
0
58
419
1.43
1.72
6.4
5.7
0.95
0.83
%
0.11
19
136
38
253
1.54
1.68
2.5
2.3
831.13
5152.37
u/l
—
8
103
10
210
0.47
1.63
1.1
1.1
0.96
0.89
g/l
—
10
210
443
4188
1.28
1.57
26.4
18.1
13.64
13.50
%
1.33
436
4149
5
15
3.35
1.52
1.0
1.6
79.20
70.93
nmol/24h
—
5
15
15
80
1.90
1.46
1.1
1.1
4.51
2.94
eliau/ml
—
8
34
54
398
1.39
1.45
6.8
5.9
0.20
0.13
%
0.18
15
114
55
407
1.39
1.45
7.1
6.2
0.00
0.15
%
1.07
14
108
16
88
1.84
1.42
3.5
3.5
5.45
4.30
e9/l
0.28
16
88
10
46
2.19
1.40
1.7
2.7
1.28
1.19
mmol/l
—
10
46
10
46
2.19
1.40
1.7
2.7
107.30
106.26
mmol/l
—
10
46
10
46
2.19
1.40
1.7
2.7
4.42
3.95
mmol/l
—
10
46
24
150
1.63
1.40
1.3
1.3
292.82
317.16
ug/g
0.18
13
79
65
498
1.35
1.39
1.2
1.2
—
—
—
0
0
5
121
0.41
1.39
1.0
1.1
—
—
—
0
0
5
121
0.41
1.39
1.0
1.1
—
—
—
0
0
77
606
1.31
1.37
1.6
1.5
—
—
—
0
0
59
449
1.35
1.32
1.9
2.1
0.00
0.05
estimate
0.78
16
107
54
406
1.36
1.31
6.1
3.8
—
—
—
0
0
10
48
2.10
1.28
2.0
3.7
1.80
3.22
nmol/l
—
10
48
11
55
2.02
1.28
2.4
2.3
—
—
—
0
0
61
779
0.76
1.26
1.6
1.6
—
—
—
0
0
6
25
2.41
1.24
1.3
1.8
1.33
7.83
u/field
—
6
18
44
326
1.38
1.18
2.1
1.6
23.32
22.25
iu/l
0.06
31
263
216
1938
1.19
1.17
5.9
3.6
0.02
0.02
estimate
0.12
62
449
10
50
2.02
1.17
1.2
1.3
—
—
nmol/l
—
0
0
5
111
0.45
1.14
2.8
3.2
4.06
11.46
umol/l
—
5
88
9
162
0.55
1.10
1.4
1.5
—
—
—
0
0
9
165
0.54
1.09
1.9
1.6
—
—
—
0
0
7
33
2.13
1.06
1.3
1.3
—
—
—
0
0
7
33
2.13
1.06
2.0
3.1
662.86
628.42
mg
—
7
33
73
593
1.27
1.05
4.2
3.9
7.33
7.05
umol/l
0.06
53
523
75
612
1.26
1.04
4.1
3.1
4.68
6.11
e9/l
0.70
64
543
12
68
1.78
1.01
1.0
1.0
1.56
1.40
g/l
0.75
12
62
208
1880
1.17
1.01
2.1
2.1
—
—
—
0
0
44
337
1.33
0.99
2.4
2.2
4.99
8.12
ug/l
1.20
38
301
29
207
1.42
0.98
2.7
2.3
33.58
5.70
iu/ml
—
9
49
15
92
1.65
0.98
8.4
4.0
—
—
—
0
0
0
30
0.00
0.97
0.0
5.4
—
120.21
—
0
24
0
30
0.00
0.97
0.0
4.4
—
7.74
—
0
30
7
37
1.90
0.94
1.1
1.2
103.00
108.35
pmol/l
—
7
37
19
126
1.53
0.92
2.1
2.6
—
—
—
0
0
33
246
1.36
0.89
2.0
2.1
0.00
0.05
estimate
—
9
88
15
95
1.59
0.88
4.2
3.7
—
—
—
0
0
218
1996
1.15
0.87
2.1
1.9
1.37
1.36
mmol/l
0.04
189
1720
160
1432
1.16
0.87
5.4
3.2
0.05
0.07
estimate
0.10
62
427
11
64
1.73
0.86
1.2
1.4
0.60
0.52
nmol/l
0.48
11
57
6
31
1.94
0.84
1.0
1.0
—
—
—
0
0
87
743
1.20
0.82
2.2
2.9
124.06
103.65
ug/g
0.27
69
599
6
32
1.88
0.82
21.3
10.8
0.60
0.62
mmol/l
—
6
32
6
32
1.88
0.82
50.3
41.6
5.95
6.70
ug/l
—
6
27
31
234
1.34
0.79
1.2
1.6
—
—
—
0
0
6
33
1.83
0.79
1.7
2.2
0.50
0.82
index
—
6
33
0
25
0.00
0.79
0.0
1.2
—
920.00
—
0
5
60
720
0.81
0.78
3.5
3.0
0.67
0.75
ug/l
0.44
38
429
15
99
1.53
0.76
5.3
3.5
8.52
7.14
pmol/l
0.30
15
99
7
38
1.85
0.73
1.0
1.0
—
—
—
0
0
20
142
1.42
0.73
2.0
1.2
—
—
—
0
0
5
25
2.01
0.73
1.6
2.5
—
—
—
0
0
49
401
1.24
0.71
1.1
1.3
134.33
229.29
u/ml
0.55
43
363
33
257
1.30
0.70
2.0
1.5
0.44
0.31
mg/l
0.42
11
115
7
41
1.72
0.70
1.0
1.2
—
—
—
0
0
7
41
1.72
0.70
1.1
1.1
—
—
—
0
0
9
59
1.53
0.68
3.3
9.1
6.52
6.82
mmol/l
—
9
52
5
27
1.86
0.68
1.2
1.8
5.56
1.35
nmol/l
—
5
21
111
986
1.16
0.67
1.9
1.7
—
—
—
0
0
131
1182
1.14
0.64
7.9
5.1
—
—
—
0
0
61
714
0.84
0.64
1.8
1.7
—
—
—
0
0
17
121
1.42
0.63
1.0
1.4
80.88
98.56
pmol/l
0.18
17
116
8
50
1.61
0.61
1.9
2.1
—
—
—
0
0
8
52
1.55
0.59
1.1
1.2
—
—
—
0
0
39
472
0.81
0.58
1.4
1.7
3.21
3.48
mmol/l
0.90
29
337
8
54
1.49
0.57
1.6
1.3
—
—
—
0
0
180
1935
0.90
0.57
3.1
2.9
—
—
—
0
0
6
36
1.67
0.57
2.2
2.8
—
—
—
0
0
20
150
1.35
0.56
1.6
2.1
11.73
4.96
iu/l
—
6
63
8
55
1.46
0.56
1.1
1.1
—
—
—
0
0
6
39
1.54
0.53
1.7
1.5
—
—
—
0
0
125
1142
1.12
0.51
3.9
3.2
324.32
335.17
umol/l
0.54
112
1018
9
65
1.39
0.50
1.1
1.2
—
—
—
0
0
9
65
1.39
0.50
1.4
1.2
—
—
—
0
0
11
76
1.46
0.48
1.0
1.1
—
—
—
0
0
18
137
1.32
0.47
1.5
1.8
—
—
—
0
0
14
102
1.38
0.47
1.1
1.1
1.00
39.92
iu/ml
—
5
25
10
68
1.48
0.47
2.5
3.5
1.30
1.11
%
—
10
62
33
273
1.22
0.47
1.3
1.7
—
—
—
0
0
7
48
1.46
0.47
1.6
1.9
—
—
—
0
0
7
48
1.46
0.47
1.0
1.2
—
—
—
0
0
17
129
1.33
0.46
3.6
3.0
57.71
56.89
%
0.08
17
129
11
152
0.72
0.45
5.0
9.4
—
—
—
0
0
10
69
1.46
0.44
1.6
1.5
—
—
—
0
0
43
368
1.18
0.44
3.0
2.7
0.13
0.46
e6/l
0.72
43
348
13
95
1.38
0.44
1.5
1.8
—
—
—
0
0
13
95
1.38
0.44
1.5
1.8
—
—
—
0
0
13
95
1.38
0.44
1.5
1.8
—
—
—
0
0
13
95
1.38
0.44
1.5
1.8
—
—
—
0
0
58
510
1.15
0.43
1.5
1.4
—
—
—
0
0
19
239
0.79
0.42
1.2
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
40.86
—
0
8
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
8
59
1.36
0.41
1.0
1.3
—
—
—
0
0
0
17
0.00
0.40
0.0
3.3
—
—
—
0
0
25
205
1.23
0.40
2.3
2.4
—
—
—
0
0
7
104
0.67
0.39
1.1
1.2
—
—
—
0
0
42
364
1.17
0.38
4.1
2.4
6.17
6.15
ph
0.03
27
235
21
172
1.23
0.34
1.1
1.2
0.99
2.88
u/ml
1.20
13
111
6
44
1.37
0.34
1.2
1.0
—
—
—
0
0
18
145
1.25
0.34
2.9
2.3
—
—
—
0
0
6
45
1.34
0.34
1.0
1.2
—
—
—
0
0
23
193
1.20
0.31
1.2
1.3
—
—
—
0
0
7
54
1.30
0.30
1.3
2.2
31.86
32.74
pg
—
7
54
51
459
1.12
0.29
2.3
2.4
29.88
33.76
u/l
0.54
43
383
7
56
1.25
0.29
1.9
3.8
—
—
—
0
0
31
270
1.16
0.28
1.3
1.2
—
—
—
0
0
101
946
1.08
0.27
1.2
1.3
10.13
29.47
iu/ml
5.78
22
279
8
64
1.25
0.27
1.3
1.3
—
—
—
0
0
8
65
1.23
0.27
1.8
4.0
—
—
—
0
0
49
443
1.12
0.27
2.9
2.5
11.18
12.91
nmol/l
0.76
44
411
11
86
1.28
0.26
1.0
1.1
—
—
—
0
0
10
77
1.30
0.26
1.3
1.3
5.40
4.63
u/ml
—
5
35
23
197
1.17
0.26
1.8
1.7
—
—
—
0
0
18
151
1.20
0.25
1.2
1.1
4.54
1.56
u/ml
0.32
12
91
10
126
0.79
0.24
1.6
1.3
—
—
—
0
0
6
85
0.70
0.24
2.0
1.5
—
—
—
0
0
120
1139
1.07
0.24
5.7
3.9
1.02
1.02
kg/l
0.08
82
758
5
38
1.32
0.23
1.0
1.1
—
—
—
0
0
5
39
1.28
0.23
6.0
2.8
—
—
—
0
0
5
39
1.28
0.23
1.2
1.4
—
—
—
0
0
25
284
0.87
0.22
1.1
1.1
—
—
—
0
0
5
41
1.22
0.22
26.2
14.3
789.40
801.17
nmol/l
—
5
41
5
41
1.22
0.22
1.0
1.3
6.90
6.35
ug/l
—
5
35
27
304
0.88
0.22
2.4
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
27
301
0.89
0.19
2.4
1.9
—
—
—
0
0
26
287
0.90
0.16
2.5
1.9
—
—
—
0
0
17
150
1.14
0.14
1.1
1.1
6.60
6.10
u/ml
—
10
98
19
170
1.12
0.13
1.3
1.2
—
—
—
0
0
11
94
1.17
0.13
1.8
3.9
25.00
25.29
mg/l
—
5
67
28
303
0.92
0.12
2.1
1.8
—
—
—
0
0
10
85
1.18
0.12
1.5
1.1
—
—
—
0
0
28
301
0.93
0.11
2.4
1.9
—
—
—
0
0
122
1191
1.03
0.09
5.0
5.0
1.54
2.31
ug/l
1.60
112
1072
16
146
1.10
0.08
1.3
1.7
239.00
199.08
u/ml
—
7
79
7
65
1.08
0.08
1.0
1.0
—
—
—
0
0
16
147
1.09
0.07
1.1
1.1
1.31
1.28
u/ml
—
9
85
8
94
0.85
0.06
1.0
1.1
—
—
—
0
0
84
860
0.97
0.06
1.3
1.3
1.29
8.23
u/ml
4.07
26
349
22
207
1.06
0.06
1.3
1.3
325.15
260.62
miu/ml
0.29
11
101
149
1511
0.98
0.05
1.5
1.5
—
—
—
0
0
18
191
0.94
0.05
2.0
1.6
20.23
7.73
u/ml
—
8
39
60
585
1.03
0.04
1.3
1.2
—
—
—
0
0
14
148
0.94
0.02
1.1
1.2
—
—
—
0
0
17
178
0.95
0.02
2.1
2.0
47.41
37.62
nmol/l
0.79
17
169
120
1191
1.01
0.01
2.0
2.0
—
—
—
0
0
39
396
0.98
0.00
4.6
4.4
3.94
18.27
ug/l
0.73
28
324
41
411
1.00
0.00
1.1
1.3
123.85
134.30
u/ml
0.06
13
171
14
136
1.03
0.00
1.9
2.0
171.29
226.59
pmol/l
1.46
14
128
9
98
0.92
0.00
1.7
1.9
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
3.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
38.43
—
0
7
5
50
1.00
0.00
3.4
3.2
63.40
54.53
%
—
5
45
0
8
0.00
0.00
0.0
3.1
—
6862.75
—
0
8
0
9
0.00
0.00
0.0
1.0
—
53.33
—
0
9
0
7
0.00
0.00
0.0
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
65
0.92
-0.00
1.5
1.3
—
60.62
—
0
6
5
58
0.86
-0.00
1.0
1.1
2.53
1.45
nmol/l
—
5
53
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint H7_NYSTAGMUS and mortality.

Females

Parameter HR [95% CI] p-value
H7_NYSTAGMUS 1.772 [1.39, 2.25] < 0.001
Birth year 0.994 [0.99, 1.0] 0.166

During the follow-up period (1.1.1998 — 31.12.2019), 175 out of 1946 females with H7_NYSTAGMUS died.

Males

Parameter HR [95% CI] p-value
H7_NYSTAGMUS 2.021 [1.62, 2.52] < 0.001
Birth year 0.986 [0.98, 1.0] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 210 out of 2046 males with H7_NYSTAGMUS died.

Mortality risk

Mortality risk for people of age

years, who have H7_NYSTAGMUS.

N-year risk Females Males
1 0.126% 0.334%
5 1.05% 2.326%
10 2.605% 5.471%
15 4.768% 10.192%
20 8.138% 17.425%

Relationships between endpoints

↥

Index endpoint: H7_NYSTAGMUS – Nystagmus and other irregular eye movements

GWS hits: 2

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data